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Abstract: 
P-thalassemia has been one of the most prevalent gene defect hemoglobinopathies in 
Asia-Pacific regions. Its common distribution and severity of symptoms have 
brought heavy burdens to both patients and public health service. Multiple 
treatments have been developed to cure this anemia, however, current treatments all 
fell in either extremely high cost or cytotoxic phenomenon. Here we propose the 
investigation of a newly developed chemical, cucurbitacin D (CuD)，as a candidate 
drug against p-thalassemia. In the in vitro experiments, this compound showed high 
efficiency in activating y-hemoglobin expression including human K562 cell lines, 
human normal bone marrow progenitor cells, and p-thalassemia major patient 
progenitor cells. All of above resembled a potential way to arise similar process in 
vivo and relieving the acute symptoms of p-thalassemia. Here we propose further 
investigations on the molecular mechanism and signal transduction pathway of CuD 
in K562 cells. Recent researches have indicated that CuD and hydroxyurea 
interacted with p38 MAPK/JAK2-STAT3 pathways and thus interfered the binding 
activity of STAT3 to regulate y-globin gene expression level. Here we provided a 
detailed investigation on the signal transduction pathways that involved during 
CuD/hydroxyurea-mediated y-globin gene expression, with the STAT3 rested at the 
core of the whole regulatory system. 
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1. General introduction 
1.1. lypes, structure and function of human hemoglobin 
1.1.1. Structure and functions of human hemoglobin 
Hemoglobin is one of the major proteins presented in erythrocytes (red blood cells), 
and its main function is to provide oxygen carrier in systematic blood circulation 
between respiratory system (lung) and tissues as an oxygen transportation mediator 
(Leeks et al. 1950). The hemoglobin is a tetrameric macromolecule, which consists 
of a tetramer assembly of four globin subunits. Each globin subunit contains a 
prosthetic heme group located at the center, with a ferrous atom chelated at the very 
central of heme group. The heme group and central ferrous atom are the main 
structure for the coupling and uncoupling of oxygen molecule. It consists of a 
porphyrin ring, which chelates one single iron atom in ferrous state via four nitrogen 
atoms on four p-orbits. The other two free p-orbit form two a-bonds, one connects 
to the histidine residue on globin main chain to hold the ferrous atom in position, and 
another is used for the binding site of oxygen molecule. Once the central iron atom 
was oxidized from ferrous state to ferric state, the oxygen-binding ability of globin 
molecule is completely lost. 
Four globin subunits are included in the hemoglobin tetramer. In adult, the four 
globin subunits are composed by two identical a-chains and two identical p-chains. 
The a- and P-chains are bonded non-covalently and held in position by means of 
hydrogen bonds, Van-der-Waals force, and hydrophobic interactions. Though the a 
and P chains do not possess much similarity on primary structure, their 
three-dimensional structures are comparable (Choi et al. 1988). 
Successful binding of oxygen molecules onto hemoglobin tetramers depends on the 
relative movements of the globin subunits. This is done by the contacts between the 
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a lp l and a2p2 stabilize the hemoglobin molecule. During the oxygenation and 
deoxygenation process, both p subunits slide relatively to the position of two a 
subimits, resulted the contact between aip2 and a2pl subunits (Lalezari et al. 1990). 
Two interchangeable conformations of human hemoglobin facilitate the loading and 
unloading of oxygen molecules, which are represented as T and R states. 
Hemoglobin molecules that are not coupled with oxygen are called T-state 
hemoglobin. Once it couples with one oxygen molecule, it triggers a change in 
conformation to the R-state, causing the heme group located at the center of globin 
subimit to adapt a more planar conformation. The confirmation change of heme 
group leads to a shifting of histidine residue approaches to the ferrous atom of heme 
group, and a more cooperative binding ability of oxygen is presented (Choi and Engel 
1988; Chakalova, Carter et al. 2005). 
One of the most distinctive characters of hemoglobin and its interaction with oxygen 
is the cooperative binding curve. As indicated, the transition from T-state to R-state 
will facilitate the affinity of globin units to the oxygen molecule, and this results a 
sigmodal oxygen dissociation curve (Chakalova et al. 2005). In other words, the 
hemoglobin affinity to oxygen climbs faster than the increase of oxygen partial 
pressure. When the oxygen partial pressure is only 26.8inmHg, the hemoglobin 
already reaches its 50% saturation level (Chakalova et al. 2005). 
Different factors play role in interfering the oxygen dissociation curve of hemoglobin, 
and two of the most important ones are environment pH value and the partial pressure 
of carbon dioxide. Under the circumstance of reduced pH value and increased C02 
pressure, the hemoglobin affinity towards oxygen tends to reduce, which favors a 
more effective unloading of oxygen in tissues with higher concentration of respiratory 
product. 
1.1.2. lypes of human hemoglobin 
Human erythrocyte progenitor cells synthesize different types of hemoglobin at 
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different developmental stages according to the places where hematopoiesis take 
place. To be detailed, during the embryonic stage, the hematopoiesis mainly takes 
place in the yolk sac, and the most synthesized hemoglobin tetramers are ^82 , 
and o2z2. In the fetal stage, the hematopoiesis location shifts to liver, spleen, and 
bone marrow, and predominant synthesized tetramer is fetal hemoglobin (a2y2). 
This fetal hemoglobin dominancy persists until the prenatal and perinatal stage, which 
is around 6 months post birth. After which, adult hemoglobin a2p2 takes place to be 
the major form of hemoglobin in body circulation, with a small percentage of a252 
and o2y2 tetramer remain to be expressed (Hoffbrand et al., 2001). 
1.2. Regulatory mechanism of human hemoglobin expression 
1.2.1. The human a and p locus 
Two different gene clusters are responsible for the direction of hemoglobin synthesis 
during development. The human a-locus, which is located on the p (short) arm of 
chromosome 16，contains seven different genes in a tandem manner. The globin 
genes sequence located on a-locus is 5，-(-\|/〔l-\)/a2-\|/al-a2-al-0-3’，with three 
pseudogenes starting with \j/. Regulation system of the a-locus is not fully clarified, 
but the order of tandem gene arrangement is known to be critical in regulation the 
expression manner, and autonomous developmental regulation also has been found in 
human transgenic mice (Albitar et al. 1991; Sharpe et al. 1993; Tang et al. 2006). 
The human P-globin gene cluster is located on the p (short) arm of human 
chromosome 11，with five functional genes arranged in a tandem manner. 
Interestingly, the arrangement of globin genes S'-e-Gy-Ay-S-P-S'determines their 
expression sequence. As mentioned, the 8 gene is firstly expressed in yolk sac 
during the developmental process. And it followed by two Gy and Ay genes, which 
are expressed in prenatal and perinatal stage. Finally, the 5 and p globin genes are 
expressed in adult stage. These gene shifts are rigidly controlled during 
developmental process, and each of the latter globin gene expression will almost 
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silence the expression of former gene completely (Grosveld et al. 1987; Simon et al. 
2001; deAndrade et al. 2006) 
1.2.2. Development of globin genes switching concept 
The initial idea of globin genes switching mechanism was raised during 1970s. It 
was considered that the colonial successions of two alternative stem cell lineages, 
which possess different gene expression programs, were responsible of the globin 
gene switching manipulation. Initially, two stem cell lineages, one possesses fetal 
hemoglobin expression program and another possesses adult hemoglobin expression 
program, coexists in the host body. During prenatal and perinatal stages the fetal 
stem cell lineages was put into proliferation and led to the production of fetal 
hemoglobin in erythrocytes and progenitor cells. After birth, the adult stem cell 
lineage was switched on and replaced fetal stem cell colonies (Weatherall et al. 1976). 
However, the existence of persisted gene expression was disputed. 
Immimohistochemical staining revealed a special cell population, which called F cells, 
was found in all adults, and the expression of fetal hemoglobin was cellular and 
lineage restricted (Boyer, Belding et al. 1975; Weatherall, Clegg et al. 1976). Other 
research results argued that the hemoglobin expression pattern in progenitor cells 
actually under changes, as one single cell lineage would be able to produce more than 
one kind of hemoglobin during all its development stages (Papayannopoulou et al. 
1976). Experimental results indicated that in vitro cultured human erythroid burst 
forming units (BFUs) was able to secrete both adult hemoglobin and fetal hemoglobin 
without segregating into colonies with different gene expression 
pattem(Papayannopoulou et al. 1977). According to which, it has been postulated 
that the globin gene switching was connected to differentiative events and 
transcriptional level control. In vivo experiments using baboon model also indicated 
that rapid regeneration of erythroid stem cells would enable premature 
terminally-differentiated cells to produce fetal hemoglobin via the perseverance of 
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primitive globin gene expression scheme(Umemura et al. 1988). And these findings 
all supported the idea that gene shifting is able to take place in one single cell lineage. 
1.2.3. Factors that regulate globin gene expression 
1.2.3.1. The locus control region (LCR) 
LCR is one of the most significant regulation components that determine gene 
expression level. It is able to regulate the expression of linked genes to 
physiological levels in either tissue-specific or copy number dependent manner at the 
ectopic chromatin sites via the looping model (Gerstein et al. 2007). 
The LCR of p-globin gene cluster was situated at 6-22kb upstream at the beginning of 
the first globin gene, e, with a length of 16kb in total. This LCR contains five 
DNAse I Hypersensitive Sites (HSs)，which carry core elements for the regulation of 
globin-gene cluster functions. Among these 5 hypersensitive sites, HSl and HS2 are 
considered to possess classical enhancer activity (Jackson et al. 2003; Jia et al. 2003). 
HSS and H4 are considered to be able of manipulating and trigger transcription 
activation via interaction with other chromatin domains (Jackson et al. 2003; Vieira et 
al. 2004; Haiju et al. 2005). HSS works as an insulator to isolate the core 
components from other globin gene promoters to prevented unexpected interaction 
and gene regulation (Li et al. 1994; Li et al. 2002). An additional HS is located at 
the 3' end of the p locus, which is specific to erythroid cells and enabling the 
stabilization between globin gene and 5' LCR hypersensitive sites (Fleenor et al. 
1993). 
1.2.3.2. The cis-regulatory elements 
Cis-regulatory elements are regions of nucleic acid sequence that regulate the 
expression of genes located on their same strand, which mainly include promoters, 
enhancers, and silencers (Wray 2007). 
Each globin gene possesses their own promoter region located upstream of the coding 
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sequence in order to recruit the binding of RNA polymerase and initiation of gene 
transcription. On the p locus, the promoter of all globin genes demonstrated 
significant homology in conserved regulatory elements. The TATA, CCAAT, and 
CACCC/GGGGTG boxes are three main cis-regulating elements found in the globin 
gene promoters of p locus (Myers et al. 1986). Each of the globin gene located on 
the p locus has one or two copies of these indicated elements. However, since 
developmental stage-specific transcription factors are essential for the shifting of 
globin gene expression, each of the promoter regions of globin genes also possesses 
unique sequence for stage-specific regulation and controlled by stage-specific 
transcription factors (Harju et al. 2002). 
Enhancers are DNA sequences that able to increase the transcription level from 
promoters by binding with proteins in a position-independent manner (Spilianakis et 
al. 2005). Mainly there are two enhancer elements found within the p locus region. 
The former one was located at 420bp following the poly-A signal of the Ay gene, and 
the latter one was situated at the 3,-end of the P-globin gene (McDonagh et al. 1991; 
Aladjem et al. 1995; Buzina et al. 2005). 
Silencers are DNA sequences that interfere with transcription activities and lead to the 
down-regulation of gene expression by interacting with binding repressor proteins 
(Temple et al. 2004). On the human (3 locus region, the most distinctive silencer 
region is located at the 5，-end area of HS5 with a tandem repeat containing sever 
continuous GATA sequence to repress the HS2 enhancer activity (Ramchandran et al. 
2000). Another two silencers containing the binding sequence of the repressor 
protein BP-1 and BP-2 was also found located at the 5'-end of the P-globin gene 
(Berg et al. 1989). 
1.2.3.3. The trans-acting factors 
The concept of trans-acting element is usually applied to indicate either a DNA 
sequence containing a gene or its expression product that will be used for the 
regulation of another target gene (Chen et al. 1996). Mainly, the trans-acting factors 
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related to globin gene regulation include GATA family, Kruppel family, STAT family 
and nuclear factor erythroid family (Foley et al. 2002; Perry et al. 2002). 
The GATA family is characterized by the target binding sequence of 
(T/A)GATA(A/G), which belongs part of the zinc-finger transcription factor family. 
Different subtypes of GATAs are found in interacting with P-promoters and are not 
tissue-specific (Zhao et al. 1999). Generally speaking, GATA-1 is the most essential 
one that involved during erythrogeneisis and megakaryocyte differentiation (Perry et 
al. 2002). The presence of GATA-1 binding sites are also been found in all globin 
promoters and HS1-HS5 site. The GATA-1 effect towards transcription activity of 
different globin genes is diverse, depending ton the transcriptional circumstance 
(Gong et al. 1991; Raich et al. 1995). It also interacts with other transcription factors 
such as EKLF and FOG in regulating the globin gene promoter transcriptional activity 
(Crossley et al. 1994; Letting et al. 2004). GATA-2 mainly is not involved at the late 
developmental stage of hematopoiesis, though some functional analysis has been 
performed during the early hematopoiesis and globin gene activation period (Anguita 
et al. 2004; Brecht et al. 2005). 
Two main subfamilies of Kriippel-like factors are connected to the hematopoiesis and 
globin gene expression. The fetal Kriippel-like factor (FKLF) mainly triggers 
embryonic and fetal globin gene expression during the early stage of human 
development (Asano et al. 1999; Asano et al. 2000; Mitsuma et al. 2005). In contrast, 
the erythroid Kriippel-like factor (EKLF) possesses more affinity to the GT/CACC 
box and regulates the adult hemoglobin production (Haiju et al. 2002). 
The Signal Transducers and Activators of Transcription (STATs) are interconnected 
with membrane-bound receptors for a wide variety of ligands, which including 
cytokings, hormones, growth factors, and neurotransmitters (Darnell et al. 1994). 
Researches have indicated that the binding of erythropoietin (EPO) to the specific 
receptors on cell surface will induce the JAK2 tyrosine kinase activity. Several 
downstream effectors of the JAK2 kinase, including STAT5 and STAT3, have been 
validated during EPO-induced hematopoiesis (Iwatsuki et al. 1997; Kirito et al. 2002). 
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1.3. The human hemoglobinopathies 
It is without doubt that the maintenance of functional hemoglobin genes to be 
essential for human health. Any kinds of disorders or abnormalities on hemoglobin 
will be considered into the clinical term of hemoglobinopathy, in other words, the 
diseases on hemoglobins. Different kinds of hemoglobinopathies have been found 
during clinical trails. And thalassemia symptoms are usually found in these patients 
with hemoglobin disorders. 
The reasons of hemoglobin abnormalities are diverse, but mostly come out from 
defective globin genes or the regulatory components. Most hemoglobin 
abnormalities will result in either reduced globin production or sequence alternation, 
which leads to the structure change of hemoglobin tetramers. The alteration of 
hemoglobin sequence usually produces structural variants and unstable hemoglobin 
presence in blood, and resulting in incapable oxygen transportation or changes in fluid 
property of blood. Incapability of oxygen transportation triggers a series of 
symptoms, mainly including tissue stress, asphyxiation, and growth retardation. The 
latter physical fluid property changes of blood leads to more severe life-threatening 
problem such as hemolytic anemia (Tischler et al. 1979). Different categories of 
thalassemia will be discussed in detail below. 
1.3.1. a-thalassemia 
a-thalassemia is characterized by inadequate synthesis of human a-globin. Upon 
clinical trails, the inadequacy of a-globin synthesis is usually contributed to the 
segment deletion of coding regions on human a-globin gene, with infrequent 
mutations or alternations on the promoter or LCR region (Albitar et al. 1991; Tang et 
al. 2006). Since one normal individual possesses four copies of the same a-globin 
gene, the thalassemia severity is greatly depending on the ration of mutant/normal 
genes. Fetus with the loss of all functional a-globin genes cannot survive until 
prenatal stage; and individuals with only one mutant gene usually do not express 
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abnormalities but still carriers. Individuals with two or three mutant a-globin genes 
may demonstrate moderate to severe anemia symptom, and splenomegaly are 
frequently found in patients (Williams et al. 2005). 
1.3.2. p-thalassemia 
P-thalassemia presents another pathological and genetic scheme which is very 
different from the a-thalassemia. The pathological origin of p-thalassemia can be 
elicited in two ways, either by mutations located at the promoter region or the 
mutations on coding region of the globin gene itself. Up to now, over 200 different 
kinds of point mutations have been reported to be responsible of p-thalassemia. 
Either of these two kinds of mutations lead to reduced production level of normal 
P-globin, which disrupt regular a to (3 globin production ratio and leaving the a-chains 
in an excess (Olivieri 1999). Excessive presence of a-chains may precipitate 
themselves in erythroids, making erythroid membrane to be fragile and finally lead to 
hemolytic anemia (Rund et al. 2005). Different from a-thalassemia, the severity of 
p-thalassemia is not determined by the copy number of normal globin gene, but by the 
amount of normal p-globin production regarding to different types of mutations. 
Mutant genes with nil p-globin production are designated as class mutant; mutant 
genes with partially functional production of p-globin are designated p+ class mutant. 
Patients with homozygous mutations are called p-thalassemia major, while patients 
with homozygous p+ mutations are called P-thalassemia intermedia. Patients who 
possess only one copy of mutations are p-thalassemia minor (Weatherall et al. 1976; 
Olivieri 1999; Rund et al. 2005). Generally speaking, four kinds of main mutations 
determined the malfunction of P-globin gene in patients, which including defective 
gene transcription, mutations in coding sequence, mutations producing abnormal 
mRNA post-processing and mutations of abnormal mRNA translation activity. 
Currently, P-hemoglobinopathies is one of the most prevalent autosomal disorders in 
Southern China (Li et al. 2006). The observed p-thalassemia defective gene carrier 
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frequency in Southern Asia communities ranges from 1.8% to 5.5% (Kazazian et al. 
1986). This genetic disorder adds extra burden to the patients' circulatory and 
respiration system, and usually result to a systematic of acute symptoms as frequently 
painful crises of joints, chest consolidation syndrome and organ dysfunctions. As a 
result, these chronic and acute symptoms may also prevalently reduce the life 
expectancy of patients (Stuart et al. 2004). Due to the prevalent defect gene carrier 
ratios, there were also distinctive amounts of patients who suffering from severe 
anemia that caused by carrying two defective genes (Kazazian et al. 1986). In order 
to extend the life expectancy of these patients, expensive treatments as blood 
transfusion and marrow transplantation methods have to be applied. Though the 
medical and public health administrative department both devote great attentions, it 
was still unlikely for the severe patients to reach their life expectancy over the age of 
25 (Lietal. 2006). 
1.3.3. Sickle cell anemia 
The sickle cell anemia is another type of p-globin gene disorder, and named after the 
occurrence of sickle-shaped red blood cell in patients. It was identified by a single 
amino acid substitution, glutamine to valine, to be responsible for the polymerized 
filamentous structure of mutant hemoglobin (HbS) appearance under low oxygen 
environment. The sickle-shaped erythrocytes are fragile and tend to rupture or 
coagulate while passing small blood vessels, interfering microcirculatory status of 
patients and thus causing vaso-occlusive crisis. The molecular detail of this 
vaso-occlusive crisis is complicated and including multiple steps as erythrocytes 
adhesion to slow-flowing venular side of vessel endothelium or post-capillary venule, 
leucocyte-endothelial adhesion, and formation of heterocellular aggregates. Finally, 
local hypoxia and propagation of occlusion results in neutrophil trans-migration and 
adds inflammation to the microvasculature hence triggering dysregulation and 
dysfunction of microcirculations (Perrine et al. 1972). 
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However, the sickle gene also has one genetic advantage that ensures its survival 
through natural selection. The heterozygous carriers are much less prone to be 
affected to the infection of Plasmodium falciparum, which prevalently causes malaria 
in tropical area. It is a delicately demonstrated example of balanced genetic 
polymorphism in humans, with three major distinctive haplotypes in Africans. 
Besides, the war and slave trade during voyage years are responsible to the gene 
dissemination and flow to North Africa, Middle Asia and even North America (Stuart 
et al. 2004). 
1.4. Current approaches towards p-thalassemia treatment 
1.4.1. Blood transfusion 
Blood transfusion is one of the traditional methods in treatment of P-thalassemia 
major and intermediate. It works by transfusing external-origin from donor into 
patients to compensate the inadequacy of hemoglobin production. This method 
greatly alleviates oxygen stress in tissue, and it also allow the patients for a better 
chance of normal growth and systematic development (Johnson et al. 1987; Castilho 
et al. 2002). 
However, the blood transfusion treatment faces severe problem on excessive iron 
deposition in tissues. Regarding to the excessive income of hemoglobin, the 
iron-containing deposition product puts stress in heart, liver, and kidney. Hence, 
patients with blood transfusion treatment require frequent administration of special 
iron-chelating agents to expel excessive iron in tissue (Schrier et al. 2005). The most 
widely applied iron-chelating drugs are deferoxamine (DFO) and deferasirox. The 
former one was developed early and needs frequent injection. The latter one 
prevented the injection constraint and it can be administered orally for more 
convenience (Borgna-Pignatti et al. 2006; Neufeld 2006). 
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1.4.2. Bone marrow transplantation 
The bone marrow transplantation treatment method was originally raised by the idea 
of replacing whole hematopoiesis system in patients and thus restoring functional 
production of erythrocytes. Similar to other organ-transplantation treatments, the 
bone marrow transplantation method greatly relies on the compatibility of HLA 
antigen isotopes between donor and patient, which is sometimes difficult to achieve. 
Even so, the great administration fee, low successful transplantation rate, and multiple 
side effects still lie between patients and administration (Benedetti et al. 1992). 
1.4.3. Drug-induced activation of fetal hemoglobin production 
1.4.3.1. Hydroxyurea 
Hydroxyurea is one common derivative from urea by adding two hydroxyl groups 
onto the NH2-residues. It was firstly observed of possessing inhibitory ability on 
ribonucleotide reductase, which hinders DNA synthesis and cancer cell proliferation. 
Hence, it was originally used for treatment of chronic myelogenous leukemia and 
other cancer symptoms (Elford 1968). During the following studies, it was 
discovered of possessing ability on inducing HbF in patients with anemia (Piatt et al. 
1984). Its mechanism was considered to be accelerating erythroid regeneration by 
inducing DNA demethylase ability and promoting S-phase DNA synthesis. As a 
result, rapid erythropoiesis enhances the chance of HbF+ cell formation via premature 
commitment of earlier progenitor cells, and hence causing y-globin gene activation 
(Galanello et al. 1988). Besides, increased hydroxyurea dose also inhibits erythroid 
burst-forming unit (BFU-E) colony proliferation, in a manner of accelerating 
erythroid regeneration and increasing the HbF production level (Yang et al. 1997; 
Baliga et al. 2000). Hydroxyurea has also demonstrated its curing effecto towards 
patients with p-thalassemia by reducing the requirement of blood transfusion, 
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increasing HbF concentration, and inhibiting extramedullary hematopoiesis 
(Loukopoulos et al. 1998; Saxon et al. 1998; Bradai et al. 2003). It is an 
FDA-approved drug currently available on pharmaceutical market. 
1.4.3.2. Butyrate and short-chain fatty acids 
The HbF induction ability of short-chain fatty acids and their derivatives, such as 
sodium butyrate, arginine butyrate and sodium phenylbutyrate, has been under 
investigation in laboratory for long time. It has been discovered that overdose 
ingestion of butyrate was able to hinder the gene switching from embryonic/fetal 
stage to adult stage in murine cell lines, chicken, and sheep (Kameji et al. 1977; 
Ginder et al. 1984; Perrine et al. 1988). It was also benchmarked on patients with 
sickle cell anemia and P-thalassemia, which demonstrated encouraging effects on 
enhancing HbF production and inhibiting BFU-E formation (Perrine et al. 1989). 
The widely accepted theory considers butyrate increases HbF production by acting as 
an histone deacetylase inhibitor thus promoting the transcription efficiency (Safaya et 
al. 1994). However, other theories focusing on the interference of p38 MAPK signal 
transduction pathways and enhancement of y-globin mRNA stability were also 
proclaimed during research (Pace et al. 2003; Weinberg et al. 2005). 
1.4.3.3. Mutagens, DNA methyltransferase inhibitors and other HbF inducible 
agents. 
Besides hydroxyurea and butyrates, drugs with properties of DNA methyltransferase 
inhibitors or DNA-binding, were also under laboratory trails for their potentials in 
eliciting HbF production. 5-azacytidine, which is a strong inhibitor of DNA 
methyltransferase, has been demonstrated able to enhance HbF production in 
thalassemia patients (Ley et al. 1982; Clegg et al. 1983). Other DNA-binding 
chemicals such as mithramycin and chromomycin, which interferes transcription via 
changing DNA structures, have also been tested for their potential in reactivating 
y-globin gene expression (Bianchi et al. 2001; Fibach et al. 2003). However, the 
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HbF inducting effects of these DNA-related drugs usually accompanied by strong 
side-effects and potential carcinogenicity, which made them inappropriate for human 
and clinical trials (Clegg et al. 1983). 
1.4.3.4. Cucurbitacin D 
Cucurbitacins are one large family of plant secretes belong to the group of plant 
triterpenoids. It derived from phytosterol cucurbitacin group, a group of plant 
steroids secreted by Cucurbitaceae family. Two of the main compounds in this 
family, Cucurbitacin B and D, were firstly isoloated from seeds of Iberis umbellata. 
Primitive experiments demonstrated these triterpenoid derivatives have the ability of 
antagonize the function of 20-hydroxyecdysone (20E)-induced morphological 
changes in Drosophila melanogaster cells in vitro (Dinan et al. 1997). Later, the 
characteristic anti-hydroxyecdysone ability was applied for the integration of 
Cucurbitacins into pesticides. During our drug-induced HbF production research, it 
was firstly isolated as a lead compound extraction from Traditional Chinese Medicine 
Trichosanthes kirilowii. Upon isolation, it demonstrated activation ability of 
y-globin gene in chronic myelogenous leukemia (CML) K562 cell line with an 
optimal concentration ED50 around lOng/ml. Comparing with the FDA-approved 
drug hydroxyurea that has an ED50 of 25)ig/ml, the Cucurbitacin D showed 
extraordinary y-globin gene reactivity. Besides, the Cucurbitacin D also 
demonstrated much lower ED50/IC50 ratio that was only 1:67 comparing with the 1:2.5 
ED50/IC50 level of hydroxyurea. These discoveries indicating the Cucurbitacin D 
may be a successful drug candidate in reactivating y-globin gene expression in 
patients with P-thalassemia (Xing 2003). 
1.4.4. Gene therapy 
The idea of correcting defective genotype of patients' hematopoietic system has been 
raised for a long time. However, the main difficulties of low level of expression and 
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transient transfection were only been overcome after the induction of lentifiral-based 
gene vectors. Researches using transgenic mice model with p-thalassemia 
symptoms indicated the thalassemia symptom could be alleviated by inducing 
lentiviral vector transfection fused with normal human p-globin gene (May et al. 
2002). However, potential danger of uncontrollable gene expression and concerns 
on virus mutation are still preventing these gene therapies from human trials. 
1.5. Research Objectives 
Two important questions have been raised based on the acquired data and previous 
research results. Since the enhancement of fetal hemoglobin production induced by 
CuD in K562 cells has been verified, it is important to explore whether the CuD 
increases the production of y-globin by up-regulating the transcription of 7-globin 
gene, and investigate any potential signal transduction pathways that have been 
involved during the induction process. The detailed proposals have been list below: 
• Detect the expression scheme of y-globin gene at different time points of post 
induction by CuD. 
參 Compare the HbF induction ability of CuD, hydroxyurea and other potential HbF 
inducers. 
參 Analyze the potential signal transduction pathways and key regulating factors 
triggered by Cucurbitacin D and hydroxyurea during y-globin gene activation. 
Investigate any potential cross-talking mechanism. 
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2. Analysis of CuD, Hydroxyurea and other inducers on the induction of a，p，y, 
6, 8 , BP-1 genes and fetal hemoglobin induction 
2.1. Introduction 
2.1.1. Properties of human K562 cell line 
The human K562 cell line is derived from erythroid progenitor cells from one patient 
with chronic myelogenous keukemia (CML). It is a multi-potential hematopoietic 
malignant cell line, carrying Philadelphia chromosome type 1 (Phi), and has the 
ability of self-differentiation into different progenitor cell lines including erythrocytes, 
granulocytes and monocytes (Lozzio et al. 1975; Koeffler et al. 1980). The K562 
cell line has been widely used during the y-globin gene activation research and 
p-thalassemia mechanisms regarding to its ability of producing fetal and embryonic 
hemoglobins under proper inducers (Rowley et al. 1981). Previous researches have 
indicated the responsive inducers of K562 cell line include butyrate, hemim， 
hydroxyurea, amifostine, and 5-azacytidine, as these drugs were also applied during 
the followed experiments (Andersson et al. 1979; Rutherford et al. 1979; Erard et al. 
1981; Rowley et al. 1981; Gambari et al. 1984; Bianchini et al. 2007). Besides, the 
human K562 cells also presented a potential unfavorable environment of human 
P-globin gene expression, though whether there was indeed any p-globin gene 
inhibition mechanism existing is still being disputed (Young et al. 1985; Mookeijee et 
al. 1992; Chase et al. 2002). 
2.1.2. Induction and measurement of fetal hemoglobin 
Two alternative methods have been developed to monitor the fetal hemoglobin 
production in vitro’ at different stages of gene expression. The real-time RT-PCR 
method, which monitors the fluctuations of cytosolic mRNA level, is applied to study 
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the individual globin-gene expression changes on the transcription level. Firstly the 
cytosolic mRNAs are extracted from total cell lysates, then a reverse-transcription 
(RT) method is performed to reverse-transcribe extracted mRNAs into cDNAs on a 
quantitative basis. Finally fluorescence-based detection method is used to quantify 
copy numbers of different desired gene in the cDNA pool. Usually an 
internal-control gene that is not easily affected by changes of external environments, 
as GAPDH or p-actin gene, will be introduced to compensate the dose differences in 
the original cell lysate. 
An alternative way of monitoring fetal hemoglobin production under drug-induced 
scheme is ELISA method. Different from the real-time RT-PCR method that 
monitors the gene expression at the transcription level, the ELISA method directly 
detects the net amount changes of synthesized fetal hemoglobin using specific 
antibody and chromogens. This method excludes the possible interference on 
post-transcriptional modifications, and it has been widely applied during 
drug-activation of y-globin gene in progenitor cell assay (lyamu et al. 2003). 
2.1.3. Induction of a, p, y, 8, e , ^ and BP-1 gene and Real-time RT-PCR analysis 
The time-dependent spectrum of y-globin gene expression in K562 cells under CuD 
induction will provide useful information on signal transduction mechanism. Since 
the induction and expression spectrum varies between different chemicals, it is crucial 
for us to understand the precise expression timeline of y-globin gene by adding CuD. 
If y-globin gene expression level increases within a short period (e.g. three hours) 
after CuD addition, it will likely be concluded that a direct response mechanism has 
been involved during the induction process like the response of Xenopus vitellogenin 
to estrogen induction (Hayward et al. 1982). Otherwise, if longer time is needed 
before y-globin gene expression was activated, it might acts through the primary 
response that may include primary response genes and then trigger the down stream 
responses which lead to the expression of y-globin gene. In order to precisely 
inspect this procedure, real-time RT-PCR should be applied. K562 cells will be 
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synchronized by starving the cell in RPMI 1640 medium with 5% fetal bovine serum. 
Then the cells will be split into pairs, one as control and one will be treated with CuD 
for 0, 4，8，12, 24，36, 48，72 or 96 h. RNA samples will be prepared from the control 
and treated cells. Real-time RT-PCR will be performed to analyze the expression of 
Y-globin gene at different time point (Gibson et al. 1996). 
2.2. Materials 
2.2.1. Chemicals and reagents 
Chemical/ Reagent Source, Catalog Number 
RPMI Medium 1640，powder Gibco 23400-021 
Dulbecco's Phosphate-Buffered Saline (D-PBS), 
Gibco 21600-010 
powder 
Sodium Bicarbonate (NaHCOs), Cell Culture Tested Sigma S5761 
Fetal Bovine Serum, Qualified Gibco 10270-106 
Antibiotic-Antimycotic (1OOX)，liquid Gibco 15240-062 
Cucurbitacin D, 1 Op,g/ml in PBS CK Lifesciences 
Hydroxyurea (HU) Sigma H8627 
3，3，，5, 5'-Tetramethylbenzidine (TMB) Sigma 527A-1KT 
Dimethyl sulfoxide (DMSO) Sigma D2650 
Sulphuric Acid (H2SO4), 98% Ajax Chemicals 
Triton X-100 Fluka 93426 
MTT Sigma-Aldrich B5525 
TrizolTM reagent Invitrogen 15596-018 
M-MLV reverse transcription kit Invitrogen 28025-013 
iTaq SYBR Green Supermix with ROX Bio-Rad 172-5852 
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2.2.2. Kits 
Kit Source, Catalog Number 
Human Fetal Hemoglobin (HbF) ELISA Quantitation Bethyl Laboratories 
Kit E80-136 
2.2.3. Buffers and solutions 
Buffer/ Solution Preparation 
1 pack of RPMI Medium 1640 powder and 
2.0g sodium bicarbonate was added to 950ml 
Milli-Q H2O. The pH of the mixture was 
adjusted with IM NaOH to pH 7.2. Milli-Q 
RPMI Medium 1640 H2O was added to make up the medium to IL. 
The medium was filtered through 022\im filter. 
Complete RPMI was prepared by adding FBS 
and PSF at final concentrations of 10% and 1% 
respectively. 
1 pack of PBS powder was dissolved in IL 
IX PBS Milli-Q H2O. The solution was autoclaved, 
cooled to room temperature and stored at 4°C. 
0.15g HU was dissolved in 3ml PBS and 
50mg/ml Hydroxyurea filtered through 0.22|im filter under sterile 
condition. 
Coating Buffer, 50mM 0.0795g Na2C03 and 0.357g NaHCOa were 
Carbonate- Bicarbonate, pH 9.6 dissolved in 100ml Milli-Q H2O. 
The Wash Buffer was freshly prepared. Tween 
Wash Solution 20 was added to IX TBS at final concentration 
of 0.05% (v/v). 
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BSA was added to IX TBS at final 
Blocking Solution 
concentration of 1% (w/v). 
Tween 20 was added to Blocking Solution at 
Sample/ Conjugate Diluent 
final concentration of 0.05% (v/v). 
10.7ml H2SO4 was added slowly to 70ml 
Stop Solution Milli-Q H2O. Milli-Q H2O was added to make 
up the solution to 100ml. 
Triton X-100 was added to Milli-Q H2O at a 
20% Triton X-100 
final concentration of 20% (v/v). 
2.2.4. Cell lines 
K562 erythroleukemia cells were cultured under the following indicated conditions: 
RPMI 1640 medium (Gibco) containing 10% fetal bovine serum (Hyclone) and 1% 
PSF antibiotic mixture (Gibco) in a humidified incubator at 37°C and 5% CO2. 
Cells were treated with Cucurbitacin D, hydroxyurea and different inducers as 
indicated concentration and time, with the cell density between 2x10"^  - 2x1cel l s /ml . 
All inhibitors were purchased from Merck Biosciences. 
2.3. Experimental procedures 
2.3.1. Hemoglobin quantity measurement by HbF ELISA 
K562 cells were seeded at an initial density of approximately 2x10^ cells/well in 
96-well plates. Two-fold serial diluted amifostine, 5-AzaC, rhEPO, HU, SPB or 
CuD was added to the wells and incubated for 5 days. Each well was seeded in 
triplicate and additional control groups were also performed to show the baseline 
expression of HbF. All plates were seeded in duplicate in order to perform separate 
MTT assay and quantitative ELISA. On the fifth day of incubation, the cell culture 
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plates were harvested by centrifuge at l,000rcf at 4 for 10 minutes. Excessive liquid 
medium was removed by vacuum sucking after centrifugation. Then cell lysate was 
prepared by adding 50ul of ice-cold CytoBuster cell lysis buffer supplied with 1:400 
protease inhibitor (Merck) into each well. The cell lysate was homogenized by 
repetitive pipetting using 200ul yellow tips until no integrate cells was visible under 
microscope. The whole plate carrying cell lysate was stored in -80 °C until use. 
2.3.1.1. MTT assay 
K562 cells, seeded at a density of IxlO'^ cells/well, were treated with different 
compounds and cultured for 3 days in 96-well V-shaped plates. Another individual 
strip of wells containing a 2-fold dilution of cell density starting from 2x10"^  cells/well 
and finished 4 dilutions serially was also applied to establish standard cell density 
curve for data gathering upon seeding. At the third day of seeding 20 i^l of MTT 
solution (5 mg/ml) was added to each well and incubated at 37°C for 2 hours. Upon 
finishing, the cell culture plates were harvested by centrifuge at 1,000rcf at 4°C for 
10 minutes. Excessive liquid medium was removed by vacuum sucking after 
centrifugation. Then 100|il of DMSO was added into each well with vigorous 
shaking to extract cell ingredients. The plate was then scanned at 570nm wavelength 
by a microplate reader. Standard curve was automatically generated using in-build 
arithmetic formula with background subtracted. 
2.3.1.2. Preparation of capture-antibody coated ELISA plates 
On the third day after application of different inhibitors and inducers, 1 [xl of capture 
antibody from Human Fetal Hemoglobin Quantization Kit (Bethyl, A80-136) was 
diluted in lOOpl of coating buffer for each well on NUNC MaxiSorp ELISA plate. 
Then the plate was incubated at 4�C overnight to ensure appropriate antibody 
adsorption on plates, altogether with a sealing membrane covering the whole plate in 
order to minimize evaporation. After incubation the antibody solution was removed 
by flipping the plate over sink and tapping gently on paper towel to drain any 
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excessive liquid. After draining, wells were washed with 200[xl of washing solution 
three times to ensure the removal of any excessive antibodies. 
2.3.1.3. Plate blocking 
200|il of blocking solution was applied to each coated wells on the ELISA plate, then 
the plate was incubated at 37�C for one hour with lid on. After the incubation in 
warm oven, blocking solution was removed by flipping the plate over sink and 
tapping gently on paper towel to drain any excessive liquid. 
2.3.1.4. Sample and standard preparation 
Upon preparation, 90 ,^1 of sample/conjugate buffer was applied to each well to be 
sampled. The plate carrying frozen cell lysate was picked up from -80 °C storage 
and quickly thawed in a 37�C water bath. Then lOjil of cell lysate was added into 
90ul sample/conjugate buffer and mixed well by shaking. Standard curve was 
prepared by diluting Human Hemoglobin Calibrator 2-folds serially according to the 
following table. Blank wells are also prepared by mixing 90)11 of sample/conjugate 
buffer and lOjil CytoBuster lysis buffer together. The ELISA plate containing both 
sample and standard wells was incubated at 37�C for 90 minutes. After incubation, 
residual sample solution was removed and the wells were washed three times of 200|il 
washing buffer each. 
Standard Concentration Sample/ Conjugate 
Calibrator RC80-135 
(ng/ml) Diluent 
500 2\il 2ml 
250 0.4ml from Step 1 0.4ml 
125 0.4ml from Step 2 0.4ml 
62.5 0.4ml from Step 3 0.4ml 
31.25 0.4ml from Step 4 0.4ml 
15.63 0.4ml from Step 5 0.4ml 
7.81 0.4ml from Step 6 0.4ml 
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2.3.1.5. HRP antibody and colorimetric detection 
Bethyl sheep anti-human fetal hemoglobin HRP-conjugated antibody was diluted at 
the concentration of 1:10000 in sample/conjugate buffer. lOOpl of HRP-antibody 
solution was applied into each wells, and the whole plate was incubated at 37°C for 
90 minutes in dark. After incubation, residual sample solution was removed and the 
wells were washed three times of 200 ,^1 washing buffer each. lOOjil of 
single-component TMB substrate solution (Merck) was applied into each well and 
incubated at room temperature until medium-dark blue color was observed. lOOjil of 
2mol/L H2S04 solution was added into each well to stop the colorimetric reaction. 
The plate was then scanned at 450iim wavelength by a microplate reader. Standard 
curve was automatically generated using in-build arithmetic formula with background 
subtracted. 
2.3.1.6. Statistical analysis 
All results are presented as means 土SEM. Statistical analyses were performed using 
t-test method. F-test was also performed before applying T-test to ensure proper data 
distribution. For more than two groups of data comparison, one-way analysis of 
variance (ANOVA) was performed to distinguish the significance. The Tukey test 
was used for multiple comparisons when ANOVA indicated statistically significant 
different between or within groups by using GraphPad Prism software. Differences 
were considered to be significant when P-factor was less than 0.05 unless specified. 
2.3.2. Preparation of mRNA extract from K562 cells 
Total RNA was isolated using Invitrogen TrizolTM Reagent protocol. 
K562 cells were seeded at 2x10^ ^ cells/ml at the initial and treated with different 
compounds. Each sample was performed in triplicate. After 48 hours of 
incubation, 50ml of cultures were collected for each sample and a total number of 
approximately 1x10^ cells were harvested by centrifuge at SOOrcf for 5 minutes at 4°C 
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using 50ml F a l c o n ™ centrifugation tubes. After washing with serum-free RPMI for 
2 times and decant, 1 ml of Trizol was added to each tubes to homogenize cell pellets 
with repetitive pipetting and vortex. Then the homogenized cell lysate was 
transferred into 1.5ml eppendorf tubes and underwent 12,500rcf for 5 minutes at 4°C 
to remove any insoluble precipitant. Clear supematants were transferred to new 
clear 1.5ml eppendorf tubes and 0.2ml of chloroform was added to each tube to 
separate aqueous and organic phase. The Trizol™ mix was centrifuged at 12,500rcf 
for 10 minutes at 4°C to ensure complete phase separation. Then the colorless 
aqueous phase was collected by aspiration and 0.5ml of isopropyl was added to each 
tube to precipitate RNA pellets. 
RNA pellets were collected by centrifuge and washed 1 times by 70% ethanol and 3 
times of absolute ethanol. Then the RNA pellets were vacuum-dry and resuspended 
in 50|il of RNAse-free water. To remove possible genomic DNA contamination in 
the purified RNA, all the RNA was subjected to DNase digestion (Promega) using the 
standard protocol provided. The concentration and purity of RNA products were 
determined by UV spectrometry. 
2.3.3. Reverse transcription and Real-time PCR analysis 
Reverse transcription and Real-time PCR consisted of the following reagents: 
M-MLV RT buffer (5x, 4|il), DTT (2ul), RNAseOut Inhibitor (40U/^il, l^il), RNA 
(O.l^ig/jil, lO^il), oligo dT(0.1^g/|il, lul), dNTP (lOmM, l^il), M-MLV reverse 
transcriptase (Ipi). The mixture was incubated at 37�C for 90 minutes and then 
stopped by heating at 95 "C for 5 minutes and quickly chilled to 4°C. RT-PCR kit 
and dNTP set were from Invitrogen and GE Lifescience respectively. The 
Real-time PCR reaction was set by adding 12.5^1 of 2X iQ SYBR Green Supermix 
with ROX (Bio-Rad), 0.5^1 of 25pmole/nl Forward Primer, 0.5^1 of 25pmole/|xl 
Reverse Primer, 6.5^1 of autoclaved Milli-Q H20 and 5\x\ of diluted cDNA. The 
cDNA was diluted 1/10 from the initial concentration for sample preparation, and a 
4-fold serial dilution consisting totally 5 different concentrations was also performed 
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to establish standard curves. NTC (non-template control) was also performed to 
eliminate any DNA contaminants from reagents. All sample wells were performed 
in triplicate. The PGR reaction was started with an initial activation step at 95 °C for 
3 minutes. 40 cycles of denaturation at 95�C for 30 seconds, annealing at 60�C (for a, 
Y, 5，8, C globin genes) or 56�C (for GAPDH, P globin and BP-1 genes) for 30 
seconds and extension at 72 "C for 40 seconds were performed. Melting curve was 
used to detect amplification efficiency and to exclude any abnormal amplification. 
Data were analyzed by the iQ5 software according to manufacture's instruction. The 
relative quantity of the different globin and BP-1 genes was normalized to the relative 
quantity of the reference gene GAPDH. GAPDH primers: upper primer: 5，-ACC 
ACA GTC CAT GCC ATC AC-3，; lower primer: 5'-TCC ACC ACC CTG TTG CTG 
TA-3，. a-globin primers: upper primer: 5'-TCC TGC CGA CAA GAC CAA CGT-3，； 
lower primer: 5’-GGC TCC AGC TTA ACG GTA TTT G-3'. P-globin primers: upper 
primer 5’-AGA AGT CTG CCG TTA CTG CCC-3'; lower primer: 5，-AGT TGG ACT 
TAG GGA ACA AAG GA-3'. y-globin primers: upper primer: 5，-CAG ACG CCA 
TGG GTC ATT TCA C-3，； lower primer: 5'-GGT GAA TTC TTT GCC GAA ATG 
GAT-3'. 6-globin primers: upper primer: 5，-CTG AGG AGA AGA CTG CTG TCA 
A-3'; lower primer: 5'-GGC ATT GTG TTC CCA AGT TCA G-3'. e-primesr: upper 
primer: 5，-CTA GCA AGC TCT CAG GCC TGG-3，； lower primer: 5’-GGC AAT 
GGC GAC AGC AGA CAC-3’. C-pnmers: upper primer: 5，-GAC TGA GAG GAC 
CAT CAT TGT G-3'; lower primer: 5'-ACA GAG GAT ACG ACC GAT AGG A-3，. 
BP-1 primers: upper primer 5'-GCT GAA AGA GGC TCA GAG AGA-3'; lower 
primer: 5’-AGG TCT GGG AAG ACA GCT TTG-3. 
2.4. Results 
2.4.1. CuD significantly upregulates HbF expression in K562 cells 
Efficacy of CuD to increase expression of HbF was compared to compounds 
previously suggested to have activity including amifostine, 5-AzaC, rhEPO, 
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hydroxyurea and SPB. Each was tested at 9 different concentrations with 2-fold 
serial dilutions. The fetal hemoglobin ELISA method measured fetal hemoglobin 
content in all treated cell lysate and absolute concentration was read out using 
standard curve. The dosage with maximal response of amifostine, 5-AzaC, rhEPO, 
HU, SPB and CuD were 625ng/mL, 400ng/mL, lOOU/mL, 25^g/mL, 100|Lig/mL and 
12.5ng/mL, respectively (Table 1，Figure 1). However at that dose, HU (25 ^ig/mL) 
caused apoptotic distorted morphology and cell death according to previous 
researches conducted in our lab, and the MTT assay also indicated a <70% cell 
proliferation ability comparing to untreated groups (data not shown). In contrast, the 
CuD (12.5 ng/mL) treated cells looked normal. The ability of CuD to induce 
hemoglobin (Hb) expression was significantly higher than amifostine, 5-AzaC, rhEPO 
and SPB. 
2 6 
Table 1. HbF quantitative data of K562 Cells treated by Different Agents (ng/10|jl lysate) 
Dilution 
(from Amifostine 5-AzaC rhEPO HU SPB CuD 
starting (lO^xg/mL) (400ng/mL) (lOOU/mL) (lOOng/mL) (lOO^ig/mL) (50ng/mL) 
dose) 
i 71士10 293士27 109士3 * 99士15 121士10 
1/2 7 0 ± 8 2 5 5 ± 1 8 7 3 ± 1 0 * 8 5 士 3 1 3 9 士 5 
1/4 6 7 ± 1 3 2 0 9 ± 1 9 6 3 ± 3 1 0 3 士 1 3 6 2 ± 1 1 5 4 士 1 0 
1/8 7 3士 9 1 7 3 ± 1 3 7 6士 7 8 0 ± 1 8 65士 8 1 5 1 士 1 2 
1 / 1 6 7 8 ± 7 1 3 2 士7 6 7 ± 5 6 5士 6 6 7 ± 3 1 1 5 士 9 
1 / 3 2 6 0 ± 4 1 0 3 士 1 6 69士 1 4 53士 1 7 6 ± 5 8 3 ± 5 
1 / 6 4 6 7 ± 8 8 3 ± 5 6 5 ± 2 5 1 土6 7 6 士6 64士 11 
1 / 1 2 8 7 4 ± 1 1 8 9 士 7 6 1 ± 4 5 1 士6 8 3 ± 8 5 4士 5 
1/256 83士3 94±8 74士8 53士 3 83±9 54±4 
Control 53 士 7 
K562 cells were treated by different agents for 5 days. The fetal hemoglobin quantity is 
measured by ELISA method. "*", indicates <50% of cell viability measured by MTT assay. 
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Figure 1. CuD induced dose-response effect in K562 cells. K562 cells were treated with 
different concentrations of either CuD or HU as indicated for 5 days. The fetal hemoglobin 
(HbF) level in cell lysate was measured by HbF ELISA kit. 
2.4.2. CuD augments a, p, y, 6, E , ^ and BP-1 genes at different level in K562 
cells 
To further confirm the mRNA level changes revealed by RT-PCR, real-time PCR 
experiments were performed to inspect different globin gene responses in K562 cells 
under the induction of CuD and HU (Figure 2). All globin genes tested showed 
different extent of increase under CuD and HU, but their dose-dependent expression 
scheme was not fully identical and somewhat different. This may imply potential 
different induction mechanisms between CuD and HU. Moreover, the expression 
level of BP-1 protein also been down-regulated, which is correspondent to the 
up-regulation of p-globin gene. 
The globin gene responses are different in CuD and HU-treated groups. In 
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CuD-treated groups, the increasing of drug induction concentration did not result in 
increased globin gene expression, a, 6, and ( globin gene demonstrated the least 
dependence on expression schemes to the increase of CuD induction concentration. 
Their expression levels were generally not affected by 16 folds increase of CuD 
concentration, y and e genes demonstrated maximum response on 3.12ng/ml of CuD 
concentration, and higher concentration of CuD reduced globin gene expression level. 
P-globin gene demonstrated a reverse-dependence scheme upon CuD induction, the 
increased CuD concentration led to gradually reduced expression level, but still higher 
than the basal expression level. 
However, all globin genes demonstrated increased expression level accompanied by 
increased hydroxyurea concentration, a, ； and P-globin genes were the most 
sensitive to hydroxyurea concentration increase, as the expression level increased 7 
folds upon 16 folds of hydroxyurea concentration, y globin gene was generally 
insensitive to hydroxyurea concentration increase, as the expression level remained 
stable. 
The human BP-1 gene expression was inhibited in both CuD and 
hydroxyurea-induced groups. Previous researches have indicated the inhibition of 
human BP-1 gene leads to increased globin genes expression, and our experiments 
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2.4.3. Cucurbitacin D-induced y-globin gene activation requires 12-24 hours in 
K562 cells 
In order to determine the exact time for the CuD-induced y-globin gene activation in 
K562 cells, a total of 12 time points were established (Figure 3) to make sampling of 
desired cell lysate and extraction of mRNA. The expression level of y-globin gene 
was evaluated by comparing with GAPDH expression level and normalized as 
expression fold using uninduced group as control. Experiment results demonstrated 
the increase of y-globin gene expression occurred at 12 hours post induction, and 
stabilized after 24 hours by a 2-fold increase. 
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Figure 3. Time-dependent response of y-globin gene expression in K562 cells under induction 
of CuD. K562 cells were treated with 3.12ng/ml of CuD and collected at different time points 
post induction as indicated. The measurement of y-globin gene expression level was 
performed by Real-time RT-PCR method. 
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2.5. Discussion 
2.5.1. Enhancement of fetal hemoglobin production using different chemical 
compounds 
Main theme of this Cucurbitacin(CuD) and hydroxyurea(HU) study was aimed in 
investigating the Optimal Biological Dose (OBD) of CuD and HU on K562 cells with 
regard to fetal hemoglobin induction. The determined OBD of CuD upon HbF 
induction in K562 cells was 3.12ng/ml，while HU was 6.25ug/ml. Previous studies 
has already determined the OBD of LC978 (Cucurbitacin D from HPLC results) by in 
vitro bioassay of total hemoglobin and HbF production (Xing 2003). And the FACS 
analysis result also revealed a defined dose of LC978 (12.5ng/ml) can induce K562 
cells in producing increased level of HbF. This experiment, using Cucurbitacin D 
obtained from commercial purificant instead of laboratory-mae HPLC extract, 
revealed similar OBD and response curve, which further validated the LC978 and 
Cucurbitacin D was the same compound. 
Apart from the FDA approved hydroxyurea (HU), a few compounds such as 
5-azacytidine, amifostine, recombinant human erythropoietin (rhEPO), and butyrate 
analogs have shown some capability of HbF activation(Xu et al. 2003; de Andrade et 
al. 2006). Several have been used clinically to treat thalassemia and sickle cell 
disease (Ji et al, 2003). Previous studies have been determined the optimum dosage 
of different HbF inducers, however, the quantitative data of net production of 
hemoglobin was not determined, as the previous study only gave out the optimum 
dosage data by indicating the positive percentage of responsive data upon drug 
induction or the result of TMB staining. Both methods lie in the same defection that 
the TMB substrate applied in the experiment was not specific towards HbF catalysis 
and chromogenic. Other cytosolic proteins that possess the ability of oxygen transfer, 
as a-globin, components of the respiratory chain and hydrogen peroxidase, are also 
able to catalyze the TMB chromogenic reaction. Hence, a more specific and reliable 
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proof for the increase of HbF production upon drug effects is definitive essential. 
It is important to make a detailed analysis towards data obtained from HbF 
quantitative data of K562 cells treated by different agents. The basal HbF 
production level of uninduced K562 cells was 53士7 ng/10|il, which mainly 
contributed to self-differentiation due to the increased cell density during induction 
assay. It was distinctive that 5-azacytidine possess the most inductivity among all 
the treated agents. It has a peak HbF production output of 293土27ng/10nl lysate at 
400ng/ml, and this inductivity was still distinctive upon 1/256 of its starting 
concentration. However, it was also the strongest mutagen among all the inductive 
agents tested, indicating it might not be appropriate for human or animal use as 
previously described (Clegg et al. 1983). CuD followed 5-azacytidine as the second 
strongest inducer with a peak HbF output at 154士 10 ng/10^1 at 3.12ng/ml induction 
concentration. Hydroxyurea demonstrated a high cytotoxicity on 100|ag/ml and 
50|j.g/ml concentration, and its peak induction concentration was 25)Lig/mL This 
phenomenon is coherence with the previous notion that the HDAC effect of 
hydroxyurea was paralleled with its cytotoxicity (Mohler 1964; Satyamoorthy et al. 
1986). Human rhEPO and sodium phenylbutyrate were also able to increase HbF 
production level in K562 cells by one fold, with amifostine possessed the lowest 
inducibility. 
For the in vitro time course assay, the net production of fetal hemoglobin in K562 cell 
increased similarly in both the CuD and HU treated cells when using their optimal 
dosage. However, the absolute amount of Hb was significantly higher in the CuD 
treated cells. The control, diluent treated cells had a small rise in HbF content which 
has been noted as the previously reported cellular self-differentiation induced by 
density increase. 
In the HbF ELISA assay, the concentration of fetal hemoglobin in cell lysate both 
increased in the CuD and HU treated groups, while the CuD treated cells have a 
significant higher synthesis compared with the HU groups. To be detailed, HU 
increased the concentration of HbF in K562 cell lysate about 2 fold comparing to its 
baseline level at the optimal inductionconcentration. In comparison, the CuD 
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increased HbF concentration in K562 cell lysate to 3 fold comparing with the baseline 
level. The absolute induction concentration of CuD (3.12ng/ml) was only 1/1000 of 
that comparing to HU (25|j,g/ml). The control group remained stable and showed a 
low level of fetal hemoglobin production. In all, the present study showed that 
cucurbitacin D (CuD) can reactivate human gamma globin gene and demonstrates a 
higher potency than the other compounds (Table 1). 
2.5.2. CuD increased HbF synthesis by increasing y-globin mRNA amount 
The K562 cell expresses all globin genes included beta-globin (Zoueva et al. 
2004)(Fordis et al, 1984). The question was answered by the analysis of mRNAs 
and HbF. The amount of a, P, y, 5，e and ^-globin mRNA have been all increased in 
both HU-treated and CuD-treated cells, while the production of y-globin was more 
significant in the CuD-treated cells (Figure 2). It is suggested that CuD enhances, at 
least in part, of HbF expression by increasing the amount of y-globin mRNA in cells. 
However, it should be clearly noticed that the globin-gene transcription scheme was 
different in CuD and HU-induced groups. For the CuD-induced group, the increase 
of mRNA level demonstrated less dependence in changes of CuD concentration, and a 
stable induction scheme can be clearly observed. In contrast, a strong 
concentration-dependent increase of mRNA level was observed in all groups treated 
by HU. The most responsive globin genes toward changes on HU induction were a, 
P, a n d � g e n e s , where a 7-10 fold changes on mRNA level could be observed. This 
may implies that CuD and HU works on different induction pathways, one to be 
dependent on the intensity of signal input, while the other one does not. 
Another different trend on CuD/HU-induced globin genes activation should also be 
noticed. Both CuD and HU are able to induce globin genes located on both a and p 
locus, regardless of the significant differences on two gene locus and their regulation 
regions. The globin genes located on a locus (a and ( genes) are more responsive 
towards drug induction, which all demonstrated at least 4 fold increase under CuD 
induction and over 6 folds under HU induction at the maximum. This suggests that 
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the regulatory region of a locus may be more responsive towards drug induction than 
those on p locus, and feasible for a future comparative research. The p-globin gene, 
though also demonstrated great response towards drug induction, should be noticed 
for its relatively low expression level. 
The real-time RT-PCR data also indicated that a 12-hours rest stage is required for 
CuD-induced y-globin gene activation. Enhancement of y-globin mRNA level was 
observed 24 hours post induction, and come to stabilized level after 36 hours. The 
delay in mRNA synthesis implies the cytological response towards CuD induction 
was unlikely to be classified into primary response, in which the inducer directly 
triggers the activation of signal cascade and transcription initialization. In contrast, 
it is likely that CuD triggers gene transcription via secondary even tertiary response. 
However, more investigation and research efforts are required to provide the fiill 
scheme of CuD induction mechanism. 
2.5.3. CuD and HU down-regulated the BP-1 gene expression 
It has been reported that the inhibition of human P-protein 1 (BP-1 gene) will enhance 
the promoter activity of the P locus (Zoueva et al. 2004). Our real-time PGR data 
showed similar inhibitory effect on the expression level of BP-1 gene under the 
induction of CuD at low concentration. However, this inhibitory effect was released 
at high CuD concentration for unknown reasons. HU-treated cell groups also 
demonstrated inhibitory effect of BP-1 gene at all concentrations tested. These 
results indicating that the drug-mediated activation of genes on p locus is likely to be 
involved with the inhibition of BP-1 expression, with detailed mechanism still under 
investigation. 
3. Determination of potential signal transduction pathways during CuD and 
HU-mediated fetal hemoglobin production 
3.1. Introductions 
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3.1.1. The p38 MAPK family 
The p38 MAPKs are one conserved subfamily of Mitogen-activated Protein Kinases 
(MAPKs), which mainly in response of cellular stress and cytokine signaling in all 
eukaryotic cells. The activity of MAPKs are regulated by the phosphorylation of 
tyrosine and threonine residues mediated by the MAPK upstream activating kinases 
(MEKs). The signal cascade from the very beginning of membrane-bound receptor 
to the MAPKs was extremely amplified by the indicated signal cascade 
(Martin-Blanco 2000). Different classes of MAPKs have been identified, which 
includes p42-p44 MAPKs (ERKs) that are activated by growth factors; 
Stress-activated Protein Kinases (SAPKs/JNKs) activated by cytokines, and p38 
MAPKs mainly in response to cellular stress. Different subfamilies of MAPKs are 
highly specified and maintained throughout each cascade and selective 
enzyme-substrate interactions in each module (Tibbies et al. 1999). 
Among the p38 MAPK subfamily, four distinct isoforms of p38 have been identified 
and named p38a，p38p，p38y/SAPK3, and p385/SAPK4. These isoforms are similar 
in their molecular size and also share about 60-75% of sequence homology. All 
these four isoforms are found able to be activated by TNF, IL-1, UV irradiation, and 
hyper-osmosis. Different p38 isoforms are tissue-specific. The p38a and p38p are 
expressed ubiquitously in all tissues, pSSy/SAPKS is mainly found in skeleton and 
smooth muscle tissue, and p385/SAPK4 is expressed in lung and kidney (Han et al. 
1994; Raingeaud et al. 1995; Jiang et al. 1996; Lechner et al. 1996; Goedert et al. 
1997). 
The connection between p38 phosphorylation and y-globin gene expression was 
firstly discovered in butyrate-induced HbF production in human K562 cells. Later, 
direct activation of p38 MAPK using anisomycin or stable vector-based 
over-expression models revealed similar phenomenon in boosting y-globin gene 
expression (Park et al. 2001). It was considered that cellular stress led by increased 
reactive oxygen or chromatin signaling were responsible for the p38 activation and 
the followed y-globin gene expression(Aerbajinai et al. 2007; Wei et al. 2007), 
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however, the full scheme of induction mechanism is still under investigation. 
The STATs are members of transcription factors that activated by JAKs via 
phosphorylation on tyrosine residues. In the rest state, the STATs usually bind to the 
membrane-bound JAKs but remain iinphosphorylated. After phosphorylation, the 
activated STATs form dimmers and translocated into nucleus, bind to the target 
sequence and modulate the expression of downstream genes (Darnell et al. 1994; 
Zhong et al. 1994). STAT3 is mainly responsible for the cytokine and growth-factor 
mediated responses and required in the fetal development stage (Heim 1999). It is 
activated by phosphorylation on Tyr705 site and which triggers dimerization, 
translocation, and DNA-binding process. However, its transcriptional activity is 
considered to be regulated by phosphorylation at Ser727 site by upstream signal either 
from MAPK or mTOR pathway (Ihle 1995; Wen et al. 1995; Yokogami et al. 2000). 
Two isoforms of STAT3a (86kDs) and STAT3p (79kDs) have been identified (Wen et 
al. 1995; Biethahn et al. 1999). 
3.1.2. The JAK2-STAT3 pathway 
The JAK family is one big membrane-bound cytokine receptor family that consists of 
JAKl, JAK2, JAK3, and Tyk2 with each of the relative molecular weight around 
120-130 kDs. This family is characterized by a carboxy-terminal kinase domain 
followed by another pseudokinase domain, and amino-terminal domains are 
conserved in all the family members (Ihle et al. 1995; Taniguchi et al. 1995). The 
JAKs have different patterns in associating with receptors regarding to different 
receptor structure. The JAK2, one of the mostly-found JAKs responsive to the IL-3 
and IL-6 induction, uses single-chain receptors for ligand connection. Excessive 
binding of ligand presence and receptor aggregation induces concomitant aggregation 
of JAK2 and facilitating the transphosphorylation of KEYY site in the kinase 
activation loop, hence dramatically increasing the catalytic activity of JAK2 itself. 
Activated JAK2 phosphorylates itself and causing the receptor and cellular substrates 
to be recruited into the receptor complex (Ihle 1995). 
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The activation of JAK2 is direct upstream event of STAT3 phosphorylation at Tyr705 
site and hence leading its dimerization and translocation. However, the role of 
phosphorylated STAT3 at Tyr705 site during y-globin gene expression is disputed. 
Researches using UT7/EP0 cells observed induction of EPO was accompanied by 
activation of JAK2 and phosphorylation of STAT3 at Tyr705 site, and implied a 
positive effect of STAT3 phosphorylation for erythroid-directed cell differentiation 
(Kirito et al. 2002). However, the IL-6 induced JAK2 activation and STAT3 
phosphorylation demonstrated inhibitory effect of y-globin gene expression (Foley et 
al. 2002). Hence, it is still not safe to conclude any certain role of STAT3 
phosphorylation during y-globin gene expression process, and additional detailed 
investigations on the regulation mechanism of STAT3 need to be performed. 
In our investigation of CuD/HU-mediated y-globin gene expression scheme, we 
applied sandwich ELISA method to detect if there was any change in 
CuD/HU-induced K562 cells, and try to make the connection between STAT3 
phosphorylation and y-globin gene expression. 
3.1.3. Fundamentals on inhibition assay of p38 MAPK and JAK2-STAT3 
pathway 
AG490 has been widely applied as a specific inhibitor of JAK2-STAT3 cascade 
mediated cellular responses. It also inhibits consititutive activation of STATS 
DNA-binding and IL-2/IL-6 induced growth of macrophage tumor cells. Though the 
AG490 treatment blocks leukemic cell growth and induces apoptosis，no harmful 
effect on normal hematopoiesis has been found (Kirken et al. 1999; Eriksen et al. 
2001; Jaleel etal. 2004). 
G66976 is a cell-permeable inhibitor of protein kinase C (PKC) activity. It 
selectively inhibits calcium-dependent PKC pathway and does not affect the 
calium-independent PKC isotypes (Martiny-Baron et al. 1993; Gschwendt et al. 1996). 
It has been reported that activation of calcium-dependent PKC pathway was involved 
3 9 
during sodium-butyrate induction and fetal hemoglobin synthesis (Rivero et al. 1998). 
D4476 is a cell-permeable triaryl-substituted imidazolo compound, which specifically 
targets the Casein Kinase I pathway. The connection between Casein Kinase I/II and 
fetal hemoglobin production have been established (Bicker et al. 1998). 
Previous research indicated the activity of glycogen synthase kinase-3P was also 
regulated by JAK2 (Gross et al. 2006). Hence, in order to investigate potential 
cross-regulation mechanism between STAT3 phosphorylation and GSK3P activation, 
specified cell-permeable GSK3P inhibitor peptide was applied to block the activity of 
cytosolic GSK3p and observe the inhibitory effects towards CuD/HU induction. 
Previous research done by our laboratory indicated the activation of MAPK family 
might be involved during CuD-induced fetal hemoglobin production. SB203580, 
SB203580 sulfone, SB202190, and SKF86002 are different kinds of chemical 
inhibitors all target the p38 MAPK pathway. SB203580 is a specific p38 MAPK 
inhibitor that does not significantly inhibit JNK/SAPK and p44/p42 ERK pathway 
(Powell et al. 2003). SB202190 inhibits p38 MAPK pathway as well as the 
activation of transcription factor 2 (ATF-2) at its optimum concentration. SB202190 
also blocks the interleukin synthesis in specific cell lines (Davies et al. 2000). 
SKF86002 acts as an anti-inflammatory drug that, by blocking the activation of p38 
MAPK pathway, inhibits cytological effects led be osmotic stress and UV-induced 
apoptosis (Frasch et al. 1998). 
SP600125 is a potent cell-permeable inhibitor that blocks activation of c-JUN 
N-terminal Kinase (JNK). It exhibits 300-fold greater selectivity for the inhibition 
on JNK pathway comparing with ERK and p38 MAPK pathway, and its effect is 
reversible in respect to ATP competition (Shin et al. 2002). PD98059 is a selective, 
cell-permeable inhibitor of MAP kinase kinase 1/2 (MKKl/2, MEKl/2) and mainly 
prevents the activation of ERK family (Means et al. 2000). U0126 is also a potent 
and specific inhibitor to MEKl/2 and mainly inhibits the activation of ERK pathway. 
Different from PD98059-mediated ERK inhibition, its inhibitory effect is 
noncompetitive with respect to the ATP (DeSilva et al. 1998). 
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3.1.4. Fundamentals on nuclear translocation of STAT3 
Electrophoresis Mobility Shift Assay (EMSA), or called Gel Shift Assay, is a 
convenient and sensitive method in protein-nucleic acid interaction detections. 
Based on the concept that the protein-nucleic acid complex possesses reduced 
electrophoretic mobility comparing with free nucleic acid probes, the EMSA produces 
retarded assay in the presence of potential protein-nucleic acid interaction (Hellman et 
al. 2007). It is commonly used in the purpose of qualitative detection, but 
quantitative results can be produced under appropriate conditions and carefully 
experiment maintenance (Fried 1989). 
The main advantage of the EMSA experiments is simplicity. It only requires very 
fundamentals of molecular biology, yet still robust enough to adapt with wide ranges 
of binding conditions. Recently introduced non-radioactive chemiluminescence 
detection method allows rapid and convenient validation of EMSA results (Berger et 
al. 1993). The detection threshold of EMSA is also highly sensitive, allowing the 
assays to be performed with small protein/nucleic acid amounts (Fried et al. 1998). 
It also adapts with wide range of nucleic acid sizes and structures as well as proteins, 
even with proteins with different stoicheometry structure or binding site distribution 
(Hudson et al. 1990; Musso et al. 2000; Tolstonog et al. 2005). These capabilities 
account the most part for the popularity of EMSA in protein-nucleic acid interaction 
studies. 
3.2. Materials 
3.2.1. Chemicals and reagents 
Chemical/ Reagent Source, Catalog Number 
RPMI Medium 1640，powder Gibco 23400-021 
Dulbecco's Phosphate-Buffered Saline (D-PBS), powder Gibco 21600-010 
Sodium Bicarbonate (NaHCOs), Cell Culture Tested Sigma S5761 
Fetal Bovine Serum, Qualified Gibco 10270-106 
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Antibiotic-Antimycotic (1OOX)，liquid Gibco 15240-062 
Cucurbitacin D, 1 O^ig/ml in PBS CK Lifesciences 
Hydroxyurea (HU) Sigma H8627 
Protease inhibitor cocktail set II Merck 539132 
Protease inhibitor cocktail set III Merck 539134 
Phosphatase inhibitor cocktail set II Merck 524625 
PhosphoSafe™ extraction reagent Merck 71296 
Dimethyl sulfoxide (DMSO) Sigma D2650 
Sulphuric Acid (H2SO4), 98% Ajax Chemicals 
Triton X-100 Fluka 93426 
Acrylamide Amersham Pharmacia 
biotech 17-1304-01 
Amido black Bio-Rad 161-0402 
Ammonium persulphate (APS) Amersham Pharmacia 
biotech 17-1311-01 
Bovine serum albumin (BSA) Sigma B6066 
Bromophenol blue Bio-Rad 161 -0404 
Calcium chloride, hydrated form Sigma C3881 
Commassie brilliant blue R-250 Bio-Rad 161-0400 
3-[Cyclohexylainino]-1 -propane sulfonic acid (CAPS) Sigma C2632 
Diethyl pyrocarbonate (DEPC) Sigma D5758 
N,N-dimethyl formamide (DMF) Sigma D4551 
Dimethyl sulfoxide (DMSO) for cell culture Sigma D2650 
Ethanol, absolute Ajax 214 
Ethylenediamine-tetraacetic acid (EDTA) Sigma E5134 
Glycerol Sigma G7893 
Glycine Sigma G8898 
Hydrocloric acid, 32% Ajax 265 
Imidazole Sigma 12399 
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Lauryl sulfate, sodium salt (SDS) Sigma L5750 
Methanol Tedia MS 1922 
N, N'-methylenebisacrylamide Amersham Pharmacia 
‘biotech 17-1304-02 
beta-mercaptoethanol Sigma M7154 
Nitro blue tetrazolium chloride (NBT) Roche 1-087-479 
Paraformaldehye Sigma P6148 
Sodium acetate Sigma S8750 
Sodium azide Sigma S2002 
Sodium bicarbonate Sigma S5761 
Sodium chloride Sigma S9625 
Sodium hydroxide Sigma S5881 
Sodium phosphate Sigma S0876 
N-N-N'-N'-Tetramethylethylenediamine (TEMED) Sigma T9281 
Tris base Amersham Pharmacia 
biotech 17-1321-01 
Triton X-100 Sigma T6878 
Trizol reagent Invitrogen 15596-026 
Trypan blue solution (0.4%) Sigma T8154 
Tween 20 Sigma P1379 
Anti-Jak2 (24B11) rabbit mAb Cell Signaling 3229 
Anti-phospho-Jak2 (Tyrl 007/1008) rabbit mAb Cell Signaling 3771 
CytoBuster Extraction Reagent Merck 71009 
SB203580 Merck 559389 
SB203580 sulfone Merck 559399 
SB202190 Merck 559388 
SKF86002 Merck 567305 
SP600125 Merck 420119 
U0126 Merck 662005 
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PD98059 Merck 513000 
AG490 Merck 658401 
D4476 Merck 218696 
G66976 Merck 365250 
GSK3p inhibitor peptide, cell permeable Merck 361546 
Anti-STAT3 rabbit (124H6) antibody (IHC preferred) Cell Signaling 9139 
3.2.2. Kits 
p38 MAP Kinase ELISA Kit Merck CBA-029 
PhosphoDetect p38 MAP Kinase (pThrl80/pTyrl82) Merck CBA-008 
ELISA Kit 
SuperSignal West Pico Complete Mouse IgG Detection Pierce 34081 
Kit 
SuperSignal West Pico Complete Rabbit IgG Detection Pierce 34084 
Kit 
STAT3 [pY705] ELISA KIT BioSource KH00481 
Hemoglobin, Plasma Kit Sigma 527A-1KT 
Human Fetal Hemoglobin (HbF) ELISA Quantitation Bethyl Laboratories 
Kit E80-136 
NE-PER Nuclear and Cytoplasmic Extraction Pierce 78833 
Reagents 
LightShift Chemiluminescent EMS A Kit Pierce 20148 
Alexa-488 Goat Anti-rabbit SFX kit Invitrogen A31628 
Biotin 3’ End Labeling Kit Pierce 89818 
3.2.3. Buffers and solutions 
1 pack of RPMI Medium 1640 powder and 
RPMI Medium 1640 
2.0g sodium bicarbonate was added to 950ml 
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Milli-Q H2O. The pH of the mixture was 
adjusted with IM NaOH to pH 7.2. Milli-Q 
H2O was added to make up the medium to IL. 
The medium was filtered through 0.22^im filter. 
Complete RPMI was prepared by adding FBS 
and PSF at final concentrations of 10% and 1% 
respectively. 
1 pack of PBS powder was dissolved in IL 
IX PBS Milli-Q H20. The solution was autoclaved, 
cooled to room temperature and stored at 4°C. 
Coating Buffer, SOmM 0.0795g NazCOs and 0.357g NaHCOs were 
Carbonate-Bicarbonate, pH 9.6 dissolved in 100ml Milli-Q H2O. 
The Wash Buffer was freshly prepared. Tween 
Wash Solution 20 was added to IX TBS at final concentration 
of 0.05% (v/v). 
BSA was added to IX TBS at final 
Blocking Solution 
concentration of 1% (w/v). 
Tween 20 was added to Blocking Solution at 
Sample/ Conjugate Diluent 
final concentration of 0.05% (v/v). 
TMB Substrate Solution Merck CL07 
10.7ml H2SO4 was added slowly to 70ml 
Stop Solution Milli-Q H2O. Milli-Q H2O was added to make 
up the solution to 100ml. 
3.3. Experimental procedures 
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3.3.1. Detection of p38 MAPK phosphorylation status 
3.3.1.1. Preparation of cytosolic protein extracts 
1x106 K562 cells were lysed in 150ul of ice-cold PhosphoSafe lysis buffer supplied 
with 1% protease inhibitor cocktail, protease inhibitor cocktail set II and III (all from 
Merck Biosciences). Cellular debris was removed by centrifugation method, and 
equal protein loading amount was determined by the Bradford method (Bio-Rad). 
Denatured cytosolic protein extracts were stored at -80°C until use. 
K562 cells were seeded in 24-well plates on IxloWell and induced by either 
3.12ng/ml Cucurbitacin D or 12.5|ig/ml hydroxyurea. Another group treated by 
200ng/ml anisomycin was applied as a positive control of p38 phosphorylation. The 
induction time was as indicated in Figure 4. Upon finishing, 1x10^ K562 cells were 
treated with 150p,l of ice-cold PhosphoSafe lysis buffer supplied with 1% protease 
inhibitor cocktail, protease inhibitor cocktail set II and III (all from Merck 
Biosciences). Cellular debris was removed by centrifugation method, and equal 
protein loading amount was determined by the Bradford method (Bio-Rad). 
Cytosolic protein extracts were stored at -80°C until use. 10|xl of cell lysate was 
used for each ELISA reaction and all inductions were performed in triplicate to 
provide statistic results. 
3.3.1.2. Quantitative measurement of phospho-p38 and pan-p38 by ELISA 
method 
3.3.1.2.1. Antigen adsorption and establishment of standard curves 
lOOpl of standard diluent buffer was added into zero wells for background correction. 
The paii/pho-p38 MAPK standards were reconstituted using standard diluent buffer. 
The initial concentration of pan-p38 standard solution was 2000pg/ml, and 
phospho-p38 standard solution was lOOimit/ml. The reconstituted solution was 
swirled gently and allowed to sit for 10 minutes to ensure complete reconsititution. 
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100^1 of either paii/pho-p38 MAPK standards was added into the first wells of 
standard wells, and a 1/2 serial dilution consisted 7 wells was made to establish the 
standard curve. Unused standard solutions were stored in -80°C. 
10|xl of cytosolic protein extract and 90|j,l of standard dilutent was mixed for each 
reaction for each well to be tested. All samples was made in triplicate to ensure 
statistical results. After mixing, the wells were covered by special adhesive 
membrane and incubated 2 hours at room temperature as indicated on kit manual. 
3.3.1.2.2. Plate washing and application of detection antibody 
The 25x concentrated washing buffer was diluted using Milli-Q water. The plate 
was decanted, washed 4 times using 250|il of washing buffer each time. 100|j,l of 
anti-p38 MAPK or anti-phospho-p38 antibody (detection antibody) solution was 
directly added into each well except the chromogen blanks. Appropriate mixture 
was applied by tapping gently on the side of the plate, \0\i\ of cytosolic protein 
extract and 90|xl of standard dilutent was mixed for each reaction for each well to be 
tested. All samples were made in triplicate to ensure statistical results. After 
mixing, the wells were covered by special adhesive membrane and incubated 1 hours 
at room temperature as indicated on kit manual. 
3.3.1.2.3. Plate washing and application of secondary antibody 
Incubated plate was decanted and washed 4 times using 250^1 of washing buffer each 
time. The anti-rabbit IgG-HRP working solution was prepared by 1:100 mixing of 
anti-rabbit IgG-HRP antibody stock and secondary antibody solution together. lOO i^l 
of anti-rabbit IgG-HRP working solution (secondary antibody) was added into each 
well except the chromogen blanks. A plate cover was applied onto the wells to 
prevent evaporation. The plate was incubated at room temperature for 30 minutes as 
indicated on kit manual. 
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33.1.2.4. Plate washing and chromogen detection 
Incubated plate was decanted and washed 4 times using 250fil of washing buffer each 
time. lOOjil of TMB substrate was quickly added into each well to generate 
chromogenic results and incubated in dark. The color generation of TMB substrate 
was monitored until a medium-dark blue color appeared, and lOO i^l of stop solution 
was quickly added into each well to stop reaction. The absorbance of each well was 
read at 450nin using a microplate reader with standard curves automatically generated 
from in-build program. 
3.3.2. Detection of signal cascade on JAK2-STAT3 pathway 
3.3.2.1. Preparation of cytosolic protein extracts for Western Blot detection 
K562 cells were induced by either 3.12ng/ml Cucurbitacin D or 12.5|ig/ml 
hydroxyurea for the time points indicated prior to cell lysis. Each 5x10^ K562 cells 
were treated with 250|i.l of ice-cold PhosphoSafe lysis buffer supplied with 1% 
protease inhibitor cocktail, protease inhibitor cocktail set II and III (all from Merck 
Biosciences), ImM PMSF and cellular debris was removed by centrifugation at 4°C. 
Protein concentrations were determined using Bradford method. 50|a,l of 5x 
SDS-loading buffer was added into the cell lysate and boiled for 10 minutes to 
denature all protein ingredients. Denatured cell lysates were stored in -80°C until 
use. 
3.3.2.2. Gel running and Western Blot detection 
For gel running, a SDS-polyacrymide discontinuous system was used for experiment. 
The discontinuous system includes 5% of pH 6.8 stacking gel and 10% pH 8.8 
resolving gel, which is effective to separate protein molecule weights ranged from 
30-150kD. To be detailed, the resolving gel solution was prepared in disposable 
plastic tube, and acrymide solution was poured into a Bio-Rad miniGel kit. Gel 
surface was overlaid by isobutanol to prevent evaporation and provide air insulation. 
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The polymerization was finished by 2 hours at room temperature. After 
polymerization was complete, the overlay was poured off and stacking gel solution 
was directly poured onto the surface of polymerized resolving gel. Immediately a 
clean Teflon comb was inserted into the stacking gel solution to provide wells, and 
polymerization was finished by 1 hour of incubation at room temperature. 
After polymerization is complete, the Teflon comb was carefully removed and wells 
were washed by running buffer to eliminate any unpolymerized acrymide. 
Denatured lysates equal to lO i^g of total protein was loaded into each lane. An equal 
volume of Ix SDS gel-loading buffer was loaded into any wells that are unused. A 
mixture of Invitrogen SeeBlue2 pre-stained protein molecule marker and Cell 
Signaling biotin-labeled molecule marker was also applied to indicate the molecular 
weight of desired protein bands during and after electrophoresis. Elecphoresis 
voltage was applied at 8 V/cm for stacking gel and 15 V/cm for resolving gel. 
For western blot, 6 pieces of 3 mm filter paper were cut into appropriate size and 
pre-soaked in transfer buffer. PVDF membrane was cut into appropriate size, 
activated in 100% methanol and rinsed with transfer buffer. The assembly was set 
up by stacking 3 pieces of filter papers, the PVDF membrane, the SDS-PAGE gel and 
another 3 pieces of filter paper at the trans-Blot SD semi-dry electrophoretic transfer 
cell (Bio-Rad) to transblot the protein onto PVDF. 15V constant voltage was 
applied for 45 minutes. The membrane was removed and blocked in blocking buffer 
for 45 minutes. 
Blocked membranes were incubated overnight at 4°C with 1:1000 dilution of 
monoclonal anti-pan-p38 and anti-phospho-p38 antibody, anti-pan-STAT3 and 
anti-phospho-Ser727-STAT3 antibody (Cell Signaling). The primary antibody 
reaction was followed by three times of washing of TBST and incubation with 
HRP-linked goat-anti-mouse and goat-anti-rabbit IgG (Amersham) at 1:10000 
dilution for 1 hour at room temperature. 
Development of membrane was performed by using SuperSignal West Pico 
chemiluminescent agent (Pierce). PVDF membranes were washed 3 times by TBST, 
and 3ml of chemiluminescent solution (1:1 mixture of A and B solution) was applied 
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for each membrane to be detected. The light signal generated was detected by a 
chemiluminescence detector (Roche), average exposure time was 2 minutes with 
adjustments on signal intensities. 
3.3.3. Quantitative measurement of phospho-STAT3-Tyr705 using ELISA 
method 
3.3.3.1. Preparation of cytosolic protein extracts 
K562 cells were seeded in 10ml culture flasks on IxloVml and induced by either 
3.12ng/ml Cucurbitacin D or 12.5^ig/ml hydroxyurea for 24 hours. Upon finishing, 
1x10^ K562 cells were treated with 50pl of ice-cold PhosphoSafe lysis buffer supplied 
with 1% protease inhibitor cocktail, protease inhibitor cocktail set II and III (all from 
Merck Biosciences). Cellular debris was removed by centrifUgation method, and 
equal protein loading amount was determined by the Bradford method (Bio-Rad). 
Cleared cytosolic protein extracts were stored at -80 °C until use. lOpl of cell lysate 
was used for each ELISA reaction and all inductions were performed in triplicate to 
provide statistic results. 
3.3.3.2. Reconstitution and Dilution of STAT3 [pY705] Standard 
The STAT3 [pY705] standard is prepared using purified, recombinant, phosphorylated 
STAT3 protein. One Unit of standard is equivalent to the amount of STAT3 [pY705] 
derived from 20 pg of STATS that was phosphorylated by activated JAK. 
The STAT3 [pY705] Standard was reconstituted with Standard Diluent Buffer. Each 
bottle of STAT3 [pY705] standard was reconstituted by adding 1ml of Standard 
Dilutent Buffer. The bottle was swirled and allowed to sit for 10 minutes to ensure 
complete reconstitution. Reconstituted standard solution was immediately aliquot 
into 150^1 volumes, labeled as 100 Units/mL STATS [pY705]. The standard was 
used within 1 hour of reconstitution. 0.25 mL of Standard Diluent Buffer was added 
into to each of 6 tubes and labeled 50, 25, 12.5, 6.25, 3.12 and 1.6 Units/mL STAT3 
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[pY705] to make serial dilutions. Unused lOOU/ml aliquoted standards were stored 
in -80 °C until use. 
The standard diluent was prepared according to the following procedure: 
lOOU/ml Reconstituted standards 
sou/ml 0.25 mL of the 100 Units/mL std. 0.25 mL of the Diluei 
25U/ml 0.25 mL of the 50 Units/mL std. 0.25 mL of the Diluent Buffer 
12.5U/ml 0.25 mL of the 25 Units/mL std. 0.25 mL of the Diluent Buffer 
6.25U/ml 0.25 mL of the 12.5 Units/mL std. 0.25 mL of the Diluent Buffer 
3.12U/ml 0.25 mL of the 6.25 Units/mL std. 0.25 mL of the Diluent Buffer 
1.57U/ml 0.25 mL of the 3.12 Units/mL std. 0.25 mL of the Diluent Buffer 
OU/ml 0.25 mL of the Diluent Buffer 0.25 mL of the Diluent Buffer 
3.3.3.3. Measurement of STAT3 [pY705] concentration in cell lysates 
The Anti-rabbit IgG-HRP (lOOx concentrate) was in 50% glycerol and was viscous. 
To ensure accurate dilution, the Anti-rabbit IgG-HRP (lOOx concentrate) was allowed 
to sit until reach room temperature and gently mixed. Anti-rabbit IgG-HRP (lOOx 
concentrate) was slowly pipet out. Excessive concentrate solution was removed 
from pipette tip by gently wiping with clean absorbent paper. For each 2 strips of 
wells, 20|xl of lOOx concentrate Anti-rabbit IgG Horseradish Peroxidase was used to 
make 2ml of working solution. 
For each experiment, 2 strips of 8-well strips was used for the assay. Extra strips and 
frame were stored in bag in the refrigerator for future use. 
100 \iL of the Standard Diluent Buffer was added into zero wells. Well reserved for 
chromogen blank was be left empty. 100 i^L of standards was added into the 
appropriate microtiter wells. 10 \iL of cleared cell lysate and 90fxL of standard 
dilutent was mixed to establish experiment reaction system. The plate was then 
thoroughly mixed using the shaking function from microplate reader. After mixing, 
wells were covered by adhesive film with plate lid, and incubated for 2 hours at room 
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temperature. 
After incubation, solution in wells was thoroughly decanted. The wells were washed 
by 250nL of washing buffer for 4 times. Then 100 i^L of anti-STAT3 [pY705] 
(Detection Antibody) solution was filled into each well except the chromogen 
blank(s). The plate was then thoroughly mixed using the shaking function from 
microplate reader. After mixing, wells were covered by adhesive film with plate lid, 
and incubated for 1 hour at room temperature. 
After incubation, solution in wells was thoroughly decanted. The wells were washed 
by 250p,L of washing buffer for 4 times. 100 \xL anti-rabbit IgG-HRP Working 
Solution was added into each well except the chromogen blank(s). The plate was 
then thoroughly mixed using the shaking function from microplate reader. After 
mixing, wells were covered by adhesive film with plate lid, and incubated for 30 
minutes at room temperature. 
After incubation, solution in wells was thoroughly decanted. The wells were washed 
by 250^L of washing buffer for 4 times. 100 fiL of Stabilized Chromogen was 
added into each well. Then the plate was incubate for 30 minutes at room 
temperature and in the dark until a medium-dark blue color was generated in wells 
with the most intense signal. After chromogenesis, 100 fxL of Stop Solution was 
added into each well to stop the reaction and solution in the wells should change from 
blue to yellow. The absorbance of each well was read at 450nin using a microplate 
reader with standard curves automatically generated from in-build program. 
3.3.4. Inhibitor assay of JAK2-STAT3 and p38 MAPK pathway 
3J.4.1. Establishment of inhibitor assay 
K562 cells were seeded at an initial density of approximately 2x10^ cells/well in 
V-bottom 96-wells plates (Coming). To be detailed, the K562 cells were initially 
seeded in 50ml culture flasks to allow cell proliferation until the final density reached 
IxlOVml. The cell cultures were centrifuged at 300g for 5 minutes in 50ml flasks to 
concentrate cells and to separate old medium. After which, the clear supernatant 
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was discarded and fresh RPMI medium supplied with 10% fetal bovine serum and 1% 
PSF was used to dilute cell pellets to a density of 4xl0Vml. lOO i^l of diluted cell 
culture was added into each well to be evaluated. 
The diluted cell culture was allowed to equilibrate in wells for 2 hours in 37°C CO2 
incubator. Then, SO i^l of different kinase inhibitors diluted by RPMI-1640 at 4x 
concentration was added into wells for inhibitor pre-incubation. The pre-incubation 
procedure was performed by incubating plate in 37°C CO2 incubator overnight. 
The Cucurbitacin D/hydroxyurea induction was performed in the next morning. 
Upon induction, SOjil of either 12.5ng/ml Cucurbitacin D or SO i^g/ml hydroxyurea 
solution diluted by RPMI-1640 medium supplied with 10% fetal bovine serum and 
1% PSF was added into each well to be evaluated to establish 3.12ng/ml of 
Cucurbitacin D or 12.5|ig/ml hydroxyurea final concentration. The plates were 
gently shaken using an ELISA shaking bed for 5 minutes to ensure complete mixing. 
The plate was then incubated in 37�C CO2 incubator for 4 days. 
Cell harvesting was applied by centrifuge plates at l,500rcf for 15 minutes. After 
centrifugation, the supernatant was discarded by vacuum suction. Then, 50|il of 
CytoBuster extraction reagent was added into each well with gentle pipetting to fully 
resuspend cells. The plates were incubated at 4°C for 15 minutes to ensure complete 
cell lysis, then the plate containing cell lysate were stored in -80 °C until use. 
3.3.4.2. HbF ELISA detection 
Refer to section 2.3.1 
3.3.5. Detection of STAT3 nuclear translocation and DNA binding affinity 
33.5.1. Preparation of nuclear extract from K562 cells 
K562 cells were initially seeded in 50ml culture flasks to allow cell proliferation until 
the final density reached IxloVml. Then cell cultures were induced by either 
3.12ng/ml of Cucurbitacin D or 12.5^g/ml hydroxyurea for 24 hours. After 
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induction, cell cultures were centrifuged in 50ml falcon tube at 300rcf for 5 minutes at 
to separate cell from culture medium. After centrifiigation, cell pellets were 
resuspended by 1.5ml of cold PBS and transferred into 1.5 ml centrifugation tube. A 
second centrifugation was performed at 500rcf for 5 minutes at 4°C. Excessive PBS 
was removed by vacuum suction and decanting. 
After decant, 20|il of packed cell volume of cells was added with 200pil of ice cold 
CER I supplied with 1% protease inhibitor, 1% phosphatase inhibitor cocktail and 
0.5mM PMSF. The tube was vortexed vigorously on the highest setting for 15 
seconds to fully resuspend cell pellet. Resuspended cell pellet was incubated on ice 
for 10 minutes. 
After incubation, ll|j.l of ice-cold CER II was added into each tube to be extracted. 
The tubes were vortexed 5 seconds on the highest setting and incubated on ice for 1 
minute. Then the tubes were vortexed again for 5 seconds on the highest settings, 
followed by centrifugation at 14,400rpm for 5 minutes at 4''C. Cleared supernatant 
containing cytoplasmic extract was quickly transferred into a clean pre-chilled 
eppendorf tube and stored in -80 "C until use. 
The insoluble pellet fraction containing nuclei was resuspended in lOOjil of ice-cold 
NER supplied with 1% protease inhibitor, 1% phosphatase inhibitor cocktail and 
O.SmM PMSF. The tube was vortexed vigorously on the highest setting for 15 
seconds to fully resuspend cell pellet. After vortexing, samples were place on ice to 
continue vortexing for 15 seconds every 10 minutes, for a total time of 40 minutes. 
After incubation, samples were centrifuged at 14,400rpm for 10 minutes at 4°C. 
Cleared supernatant containing nuclear protein extract was aliquoted into PGR tubes 
at lOOjil each. All extracts were stored at -80 °C until use. 
3.3.5.2. EMSA detection of transcriptional factors binding to y-promoter region 
33.5.2.1. 3' end-labeling of EMSA probes 
A double-stranded oligonucleotide containing a STAT-3 consensus sequence 5'-ACA 
CTC GCT TCT GGA ACG TCT GAG GTT ATC AAT AAG-3' and its 
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complementary sequence was synthesized to make the probe. Equal volume of 
oligonucleotide diluted in TE buffer was mixed well at a volume of 100|xl in PCR 
tubes. The probe annealing was performed by using a PCR machine with the 
following program: 
Temperature Time 
95�C 5 minutes 
O.rC /second decrease to 40�C ~ 
Quickly chill to 4�C 一 
Annealed probe was aliquoted and stored in -80 °C until use. 
The 3，biotin end labeling of EMS A DNA probe was performed by using Pierce 
Biotin 3' End Labeling Kit. 
Kit components were thawed on ice. Just before use, 4\i\ of 17U/pl of TdT stock 
was diluted by 30^1 of TdT reaction buffer to achieve 2U/|xl final concentration. 
Reaction system was established by mixing components according to the following 
chart: 
Component Volume Final Concentration 
Ultrapure water 25|j,l ~ 
1 Op.1 of 5x TdT reaction buffer 10|j,1 Ix 
5|xl of 1|jM unlabeled oligo 5|il lOOnM 
5^1 of biotin-ll-UTP S i^l 0.5^M 
Diluted TdT (2U尔1) 5\i\ 0 . 2 _ 
Total Volume 50^il -
After mixing, the reaction system was incubated at 37°C for 30 minutes to allow the 
addition of biotin onto the 3’ end of DNA probe. Then 2.5^1 of 0.2M EDTA was 
added into reaction system to quench TdT activity. 50^il of chloroforaiiisoamyl 
alcohol was added into each reaction system, mixed well, and incubated 5 minutes at 
room temperature to extract TdT. Incubated PCR tubes were put into centrifugation 
for 2 minutes at 16,000rcf to separate organic phase from aqueous phase, separated 
aqueous phase was stored at -80�C until use. 
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3.3.5.2.2. Dot blotting for labeling efficiency estimation 
Prior to the EMS A binding experiment, the 3’-biotin labeling efficiency was estimated 
by using dot blots and developed by Pierce Lightshift Chemiluminescent EMSA Kit. 
One 6x8cm of positively-charged Nylon membrane was hydrated in TE buffer for 10 
minutes to ensure complete equilibration. One sample of Biotin Control Oligo stock 
and Unlabeled Control Oligo was diluted by TE buffer to make a final concentration 
of SOnM oligo stocks. DNA probes used for EMSA experiment was also diluted to 
50nM concentration using TE buffer. 
In microcentrifuge tubes, a series of oligo standards were established using the 
following table 
Component % Biotin 
100 75 50 25 0 
Biotin Control Oligo (SOnM) 12 9 6 3 0 
Unlabeled Control Oligo (SOnM) 0 3 6 9 12 
TE, pH 8.0 48 48 48 48 48 
Total Volume 60 ,^1 60^1 60|il 60^1 60 ,^1 
50p,l of the oligo working stocks was pipette into wells A1-A5 of a 96-well dilution 
plate. Then a 10-fold dilution of the test TdT labeling reaction in TE buffer was 
established to achieve a final concentration of lOnM. 50^1 of each lOnM test DNA 
samples was place into unused A wells of the 96-well plate, and also a series of 
two-fold dilutions of standards and samples were established by removing 25|xl 
aliquots from all A wells and mixing them with 25|il of TE buffer in corresponding B 
wells. The serial dilution was continuously performed down the plate through H 
wells. 
Equilibrated nylon membrane was placed onto a clean dry paper towel to absorb any 
excessive residual buffer. 2|il of each samples and standards were blotted onto the 
membrane. Blotted samples and standards were allowed 30 seconds for full 
absorption into membrane. After which, nylon membrane containing probes was 
immediately crosslinked by using UV-crosslinker at 120mJ/cm^ each side. 
56 
Crosslinked membrane was stored at 4°C until detection. 
Development and detection of crosslinked dot-blot membrane was performed using 
Pierce LightShift Chemiluminescent EMSA Kit. 
3.3.5.2.3. EMSA binding reaction and non-denaturing gel electrophoresis 
5x EMSA binding buffer was prepared as described before on the following recipe: 






The binding buffer was completely mixed and sterile filtered. After establishment, 
the binding buffer was stored at -20'C before use. 
The EMSA reaction system was then established. For the binding assay group, 8[il 
of binding buffer，4p,l of biotin-labeled probe and 24|a,l of ddH20 was mixed and 
aliquot into 9}il each. For each 9\i\ aliquot, Ipl of lOng/^il nuclear extract from 
untreated, Cucurbitacin D-treated or hydroxyurea-treated samples was added into and 
mixed thoroughly. For the cold-probe competitor group, 8|il of binding buffer, 4^1 
of unlabeled cold probe and 20|j,1 of ddH20 was mixed and aliquot into 8^1 each. 
Ijxl of lOng/jil nuclear extract from untreated, Cucurbitacin D-treated or 
hydroxyurea-treated samples was also added into buffer system, mixed thoroughly, 
and incubated 5 minutes at room temperature. Then 1 |il of biotin-labeled probe was 
added into each of the competitor reaction system and thoroughly mixed. Both the 
binding and competitor reaction system was incubated on ice for 20 minutes before 
loading to gel. 
Tris-boric acid-EDTA buffered non-denaturing gel was prepared using Bio-Rad 
miniGel electrophoresis apparatus. One gel was prepared according to the following 
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chart. 
30% Acrylamide 1.17ml 
5x TBE 0.65ml 
70% glycerol 0.51ml 
ddH20 4.23ml 
10% AP 36^il 
TEMED 4^1 
The gel was allowed to polymerize for 2 hours at room temperature. After 
polymerization, gel electrophoresis unit was filled with 0.5x TBE to the maximum 
capacity to reduce any heat generated during electrophoresis. A pre-nmning was 
applied by using 80V power supply for 60 minutes. 
After incubation, 2 .^1 of 6x EMSA loading buffer was added into each of the reaction 
systems and mixed well to quench binding reaction. lOpl of mixture was carefully 
loaded into each well to be electrophoresised. The electrophoresis procedure was 
accomplished by using 80V voltage for 40 minutes until the fast-running 
bromophenol band reached 1cm above gel bottom. 
3.3.5.2.4. Membrane development and chemiluminescence detection 
One 6x8cm of positively-charged Nylon membrane was hydrated in TE buffer for 10 
minutes to ensure complete equilibration. Equilibrated nylon membrane was placed 
onto a clean dry paper towel to absorb any excessive residual buffer. 2^1 of each 
samples and standards were blotted onto the membrane. Blotted samples and 
standards were allowed 30 seconds for full absorption into membrane. After which, 
nylon membrane containing probes was immediately crosslinked by using 
UV-crosslinker at 120mJ/cm^ each side. Crosslinked membrane was stored at 4°C 
until detection. 
Blocking and 4x washing buffer from LightShift Chemiluminescent EMSA Kit was 
gently warmed to 37�C in water bath until all particulate and residual salt has been 
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dissolved. 10ml of blocking buffer was added into water reservoir with crosslinked 
nylon membrane. Membrane was blocked by gently shaking at room temperature 
for 15 minutes. 
Conjugate/blocking buffer solution was prepared by adding 50^il of stabilized 
streptavidin-HRP conjugate to 15ml of blocking buffer. Excessive blocking buffer 
was decanted from membrane, and the membrane was placed in clean new reservoir 
containing 15ml of conjugate/blocking solution. The streptavidin-biotin binding 
reaction was performed by incubation at room temperature for 15 minutes with gentle 
shaking. 
Ix washing solution was freshly prepared by mixing 40ml of 4x wash buffer with 
120ml ddH20. After incubation, membrane was decanted on paper towel to absorb 
any excessive solution, then washed 4 times using 20ml of Ix washing solution for 5 
minutes each time with gentle shaking. 
After washing, membrane was decanted on paper towel to absorb any excessive 
solution. Decanted membrane was then applied into a new water reservoir 
containing 30ml of substrate equilibration buffer for osmosis equilibration. The 
incubation was performed by gentle shaking for 5 minutes at room temperature. 
After washing, membrane was decanted on paper towel to absorb any excessive 
solution. Decanted membrane was placed in a clean container. Substrate working 
solution was then prepared by 1:1 mixture of luminol/enhancer solution and stable 
peroxides solution together. Mixed substrate working solution was poured onto the 
membrane as it completely covered membrane surface. The membrane was 
incubated in substrate working solution for 5 minutes at room temperature without 
shaking. 
After incubation, membrane was decanted on paper towel to absorb any excessive 
solution. Detection of chemiluminescence signal was accomplished by using Roche 
F1 chemiluminescence detector. The exposure time was 7 minutes. Collected data 
was gathered and transformed into visible image using in-build software from 
detector. 
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33.5.3. Preparation of K562 samples for immunofluorescence detection 
3.3.5.3.1. Slide coating for cell capture 
8-cells chambered slide was coated with poly-l-lysine to ensure appropriate adhesion 
of K562 cells onto slide. To be detailed, 1ml of lOx concentrated poly-l-lysine 
solution was mixed with 1ml of PBS and 8ml of ddH20. The diluted poly-l-lysine 
solution was applied to the chambers at 1 ml/chamber, and the slide was incubated 2 
hours at room temperature. After incubation, the chambers were thoroughly washed 
by ddH20 and allowed to dry at room temperature. 
3.3.5.3.2. Preparation of cell slide 
K562 cells were initially seeded in 10ml culture flasks to allow cell proliferation until 
the final density reached IxloVml. Then cell cultures were induced by either 
3.12ng/ml of Cucurbitacin D or 12.5|a,g/ml hydroxyurea for 24 hours. After 
induction, cell cultures were centrifuged in 15ml falcon tube at 300rcf for 5 minutes at 
4�C to separate cell from culture medium. After centrifugation, cell pellets were 
resuspended by 0.5ml of PBS. 
Resuspended cells in PBS were added into cells on the chamber slide respectively to 
the induction status. The chamber slide containing resuspended K562 cells was then 
covered with chamber lid, and incubated in 37"C incubator supplied with 5% CO2 for 
30 minutes to ensure complete cell adhesion to slide. 
33.5.3.3. Sample fixation and antibody probing treatment 
After incubation, excessive PBS in the slide chamber was quickly purged out, and the 
chamber slide was put onto paper towel with bottom-up to absorb excessive liquid. 
For each chamber, 1ml of 4% para-formaldehyde in PBS was quickly added into the 
well to fix cells. Fixed slide was incubated at 4�C for 1 hour to ensure complete 
fixation. 
After fixation, excessive para-formaldehyde was removed from chamber wells by 
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vacuum suction. The chamber slide was then put onto paper towel with bottom-up 
to absorb excessive liquid. The chamber wells were washed three times using 1ml 
of PBS each for 5 minutes to ensure complete removal of residual para-formaldehyde. 
Washed chamber slide was permeablized by incubating with 0.05% Triton X-100 in 
PBS for 5 minutes. Following permeablization, the chamber wells were again 
washed three times using 1ml of PBS each for 5 times to remove residual Triton 
X-100. After which, 200^1 of highly cross-absorbed blocking reagent was applied 
into each well to block nonspecific sites. The chamber slide was incubated at room 
temperature for 1 hour to ensure complete blocking of nonspecific sites. 
After blocking, the blocking reagent was removed by flipping chamber slide onto 
paper towel. Then 200^1 of 1:400 mouse anti-STAT3-antibody (124H6) diluted in 
blocking reagent was applied into each well. The chambers were sealed by parafilm 
with slide on, and incubated at 4°C overnight for maximum absorption of primary 
antibody. 
After overnight incubation with primary antibody, he chamber wells were washed 
three times using 1ml of PBS each for 5 minutes to ensure complete removal of 
residual antibody. Then 100|xl of 1:1000 goat anti-mouse Alexa-488-conjugated 
detection antibody (highly cross-absorbed) diluted in PBS was applied into each well. 
The slide was incubated at 37"C for 1 hour. 
After incubation, chamber wells were washed three times using 1ml of PBS each for 5 
minutes to ensure complete removal of residual antibody. Then the chamber was 
removed altogether with rubber sealing ring. 50|il of Invitrogen Antifade mounting 
reagent was applied onto slide and mounted. Mounted slide with cover glass was 
wrapped with aluminum foil and stored in 4�C until detection. 
3.3.5.3.4. Sample imaging and immunofluorescence detection 
Immunofouorescence detection was performed by using Bio-Rad Radiance 2100 
confocal imaging system. The laser-emitting module was pre-heated for 30 minutes 
before detection. Upon detection, slide containing cell samples was mounted with 
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Carl-Zeiss Immersol 518N immersion oil to enhance imaging quality. The 
microscopic detection was then performed by using Argon laser wavelength 488nm, 
60x objective lens, 50 lines/second scanning speed and 512x512 image size. 
3.4. Results 
3.4.1. Activation of p38 MAPK pathway and STAT3 phosphorylation by 
hydroxyurea 
3.4.1.1. The p38 MAPK pathway is activated by hydroxyurea, but not activated 
by Cucurbitacin D 
We examined whether the phosphorylation level of p38 MAPK was altered by the 
induction of either 3.12ng/ml of Cucurbitacin D or 12.5|ig/ml of hydroxyurea during 
6 time points in 24 hours of induction period. The indicated concentration of 
inducing drugs has been verified that they would not interfere with cell viability by 
MTT assay (data not shown). Fig. 6 demonstrated the phospho-p3 8/pan-p38 ratio 
changes at different time points post induction, plus the positive control of p38 
activation induced by anisomycin. It can be clearly observed that the 
phospho-p3 8/pan-p3 8 ratio was increased 12-24 hours post induction for 2 folds in 
hydroxyurea-treated groups, but not in Cucurbitacin D treated groups (P<0.05). In 
all, after 24 hours of induction we observed a 2.3-fold induction of phospho-p38 
MAPK under hydroxyurea induction, and direct activation of p38 by anisomycin also 
confirmed that our K562 cells were responsive to p38 MAPK inducers. This result 
indicated that p38 MAPK activity is induced in a manner by the y-globin inducer 
hydroxyurea. However, the Cucurbitacin D, although it also possesses the ability of 
inducing y-globin, cannot elicit similar effects. Hence, it may suggest two different 
induction mechanisms that lie between Cucurbitacin D and hydroxyurea. 
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Figure 4. Time-dependent phosphorylation level of p38 MAPK kinase under the induction of 
CuD or HU in K562 cell line. K562 cells were treated with 3.12ng/ml of CuD or 12.5Mg/ml of 
HU. Cells were collected at different time points as indicated for the measurement of 
phospho-p38 and pan-p38 using ELISA method. Y axis represents the phospho-p38/pan-p38 
ratio after induction, ani: Anisomycin-treated group for positive p38 activation control. *: 
P<0.05 
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3.4.1.2. Increased p38 phosphorylation level elicits STAT3 phosphorylation at 
Ser727 site 
It has been reported that the p38 is one of the direct upstream activators of STAT3 and 
causes its phosphorylation on Ser727 site. Western blot detection results 
demonstrated enhanced phosphorylation level of Ser727 site following p38 MAPK 
activation in hydroxyurea-induced groups 8-12 hours post induction (Figure 5A, 5B). 
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Figure 5. Enhanced p38 phosphorylation and STATS phosphorylation level at Ser727 site in 
K562 cells upon 12.5pg/ml hydroxyurea induction. A: Western blot result of 
phospho-STAT3-Ser727 and phospho-p38 upon hydroxyurea induction in different time points, 
total STATS and p38 amount were served as an internal control. B: Quantitative analysis 
result of increased phospho-STAT3-Ser727 level upon hydroxyurea induction. K562 cells 
were treated with 12.5ng/ml of HU, and collected at different time points as indicated for the 
measurement of phospho-p38-Ser727. Y axis represents the phospho-p38-Ser727/pan-p38 
ratio after induction. P<0.05;，P<0.01 
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3.4.2. Activation of JAK2 and STAT3 phosphorylation by Cucurbitacin D 
3.4.2.1. Cucurbitacin D promotes JAK2 activation 
JAK2 is one of the most important upstream activator molecules of STAT3, and its 
activation leads to the phosphorylation of STAT3 on residue Tyr705 site. Hence, 
western blot detection was performed to investigate whether Cucurbitacin D and 
hydroxyurea would activation STAT3 via JAK2 pathway. The western blot result 
(Figure 6A, 6B，6C) indicated enhanced phosphorylation level of JAK2 in 
Cucurbitacin D-induced groups, while no similar increase of phosphorylation was 
found in hydroxyurea-induced groups. Altogether with the result of 
p-STAT3-Ser727 introduced by hydroxyurea, these experiment outputs suggest two 
different induction pathways may lie between Cucurbitacin D and 
hydroxyurea-induced y-globin gene activation. 
3.4.2.2. Cucurbitacin D and hydroxyurea promote STATS phosphorylation at 
TVr705 site 
ELISA experiments using anti-phospho-STAT3-Tyr705 kit demonstrated that the 
phosphorylation level on STAT3 Tyr705 site increased two fold in both Cucurbitacin 
D and hydroxyurea-induced groups after 24 hours of drug treatment (Figure 7). 
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Figure 6. Enhancement of JAK2 and STATS phosphorylation in K562 cells under CuD and HU 
induction. K562 cells were treated by 3.12ng/ml CuD or 12.5pg/ml hydroxyurea for 24 hours. 
A: 3.12ng/ml CuD treated cell lysate using pan/phosphor-JAK2 antibody; B: 12.5[jg/ml HU 
treated cell lysate using pan/phosphor-JAK2 antibody; C: quantitative JAK2 phosphorylation 
data from CuD/HU-treated cell lysate; D:STAT3 Tyr705 phosphorylation level, he 
phosphor-STAT3-Tyr705 level in cell lysate was measured using ELISA method. **: P<0.01 
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3.4.3. Basal activity of signal transduction pathways is essential for HbF 
induction 
3.4.3.1. Activation of y-globin gene requires presence of basal phosphorylation 
level of p38 MAPK 
In order to validate that whether even basal phosphorylation level of p38 MAPK is 
required for y-globin expression, different inhibitors of MAPK pathway and its 
components, including JNK, ERK and p38 inhibitors, were applied to block specific 
signal transduction pathway during our drug induction assay. The production 
efficiency of fetal hemoglobin was observed to evaluation the blocking effect of 
different inhibitors towards y-globin gene expression. The representative chart is 
shown in Figure 7. Both Cucurbitacin D and hydroxyurea significantly increased 
fetal hemoglobin concentration in cell lysates by 3 fold (PO.Ol) as previously 
indicated. By contrast, pretreatment with 10|iM of p38 MAPK inhibitors 
(SB203580, SB203580 sulfone, SB202190 and SK86002) significantly inhibited the 
fetal hemoglobin production in all experimental groups regardless of different 
inducing drugs. However, groups pretreated by JNK inhibitor (SP600125) and ERK 
inhibitors (PD98059 and U0126) did not represent similar inhibitory effects. Hence, 
we may conclude that the presence of p38 MAPK, even at the basal level, plays an 
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Figure 7. Effects of different MAPK family inhibitors on the fetal hemoglobin (HbF) production 
in K562 cells upon CuD or HU induction. K562 cells were firstly pre-treated by different 
inhibitors for 24 hours at the concentration indicated, then induced by either 3.12ng/ml CuD or 
12.6|jg/ml hydroxyurea for 5 days. The hemoglobin level in total cell lysate was measured by 
using HbF ELISA kit. JNK inhibitor SP600125： ERK inhibitors: PD98059. U0126; p38 
inhibitors: SB203580, SB203580 sulfone. SB202190, SKF86002. A: 3.12ng/ml Cucurbitacin 
D-treated groups; B: 12.5fjg/ml hydroxyurea-treated groups. F<0.05; **: P<0.01, all 
significance were achieved by comparing with uninduced group. 
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3.4.3.2. Inhibition on JAK2-STAT3 pathway results in reduced fetal hemoglobin 
production 
Besides p38 MAPK, other potential pathways that have been reported to be involved 
during y-globin gene activation were also studied, which included JAK2-STAT3, CKl, 
GSK3P and PKC. Blocking effect of different inhibitors towards fetal hemoglobin 
production under Cucurbitacin D and hydroxyurea induction is shown in Figure 8. 
Results indicated that the inhibition of JAK2-STAT3 pathway, which was considered 
cross talking with p38 MAPK pathway, resulted in reduced fetal hemoglobin 
production in both Cucurbitacin and hydroxyurea-induced groups. Inhibition in 
PKC pathway also resulted in reduced fetal hemoglobin production in 
hydroxyurea-induced groups, but not found in Cucurbitacin D-induced groups. The 
results indicated that both p38 MAPK and JAK2-STAT3 pathways are essential in 
Y-globin induction by Cucurbitacin D and hydroxyurea. 
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Figure 8. Effects of different inhibitors on the fetal hemoglobin (HbF) production in K562 cell 
line upon CuD or HU induction. K562 cells were firstly pre-treated by different inhibitors for 
24 hours at the concentration indicated, then induced by either 3.12ng/ml CuD or 12.5|jg/ml 
hydroxyurea for 5 days. The hemoglobin level in total cell lysate was measured using HbF 
ELISA kit. AG490: JAK2 inhibitor; D4476: CK1 pathway inhibitor; G66976: PKC inhibitor; 
inhibition of GSK3beta pathway was performed by using specific cell-permeable inhibitor 
peptide. 
3.4.4. Translocation and DNA binding of STAT under Cucurbitacin D induction 
3.4.4.1. Cucurbitacin D and hydroxyurea both enhance binding affinity of 
transcriptional factors to the Gy/Ay promoter 
To validate the changes of binding status on the promoter region of y-globin gene, one 
consensus sequence containing a STATS-link binding sequence indicated in previous 
research (5'-ACA CTC GCT TCT GGA ACG TCT GAG GTT ATC AAT 
AAG-3')(Foley et al. 2002) was chosen to perform gel retardation assay. This 
sequence included a STAT3-like binding sequence (5,-TTC TGG AA-3') between +9 
to +16 to the location of CAP site, and similar to the STATS consensus sequence 
TT(N)4.5AA. The preparation of nuclear extract as described previously in the 
material and methods section, and a radioisotope-free gel retardation assay was 
72 
performed accordingly with equal protein loading. EMS A results revealed enhanced 
binding affinity to the STAT3-like consensus sequence in both Cucurbitacin D and 
hydroxyurea-induced nuclear extracts, and this effect could be successfully competed 
by lOOx excessive cold probes (Figure 9). The results further confirmed the 
translocation of STAT3 into nucleus and their interaction with y-promoter region, 
which played an important part in the activation of y-globin gene. 
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Figure 9. The structure of y-promoter sequence and EMSA result. A: The v-promoter 
sequence includes following regulatory elements: STAT3-like sequence, AySTATS sequence, 
including a stage selector element (SSE)-like element, GATA-1 site and an AT-rich sequence 
located in +28—32. The oligo sequence used in EMSA starts from +1 to +36, including the 
STAT3-like and AySTATa sequences (5’-ACA CTC GCT TCT GGA ACG TCT GAG GTT ATC 
AAT AAG-3'). B: EMSA result shows enhanced binding affinity to the oligo. K562 cells were 
induced by either 10ng/ml Cucurbitacin D or 20叩/ml hydroxyurea for 24 hours. The nuclear 
extracts were collected and binding reaction was performed with the presence of poly dIdC to 
prevent unspecific binding. The enhanced binding affinity could be successfully competed by 
100x cold probe. 
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3.4.4.2. Cucurbitacin D and hydroxyurea induces nuclear translocation of 
STAT3 
The translocation of transcription factors from cytoplasm to nucleus is essential for 
the activation of target genes. Hence, we also performed investigation towards the 
nuclear migration of STATS induced by Cucurbitacin D and hydroxyurea. Confocal 
microscopy results of K562 cells treated with anti-STAT3 antibody also revealed 
increased presence of STAT3 in nucleus (Figure 10). These results suggested that 
the activation of y-globin gene was accompanied with the translocation of STAT3 
under drug induction. 
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Figure 10. Confocal microscopy images of K562 cells demonstrating the translocation of 
STATS. K562 cells were treated by either 10ng/ml Cucurbitacin D or 20|jg/ml hydroxyurea for 
3 hours before fixation. All images were taken under same magnificent and scanning 
parameters. Increased presence of STATS in nuclear is clearly visible. 
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3.5. Discussion 
3.5.1. The role of p38 MAPK activation during y-globin gene activation 
The original idea of p38-mediated y-globin gene expression was noted during the 
investigation of HDAIs and their effects toward globin gene regulations (Pace et al. 
2003). Two different HDAIs, sodium butyrate and trichostatin, have been identified 
to be able of activating p38 MAPK pathway besides their effects on histone 
hyperacetylation. Experiments using hemin，one compound which is able to induce 
Y-globin gene expression but cannot activate p38 MAPK pathway, also confirmed the 
relationship between p38 MAPK and y-globin gene expression as the pre-treatment of 
p38 inhibitors did not interfere the expression of y-globin gene. Up to now, several 
trans-activators of butyrate responsive elements have been identified (Bohan et al. 
1989; Daita et al. 1998; Pace et al. 2000). 
In this study, a potential relationship between hydroxyurea-induced p38 MAPK 
activation and y-globin gene expression has been presented. The hydroxyurea has 
been reported able to activate p38 MAPK and trigger cell differentiation in human 
K562 cell line (Park et al. 2001). The effect of hydroxyurea on cellular 
differentiations also shares some similarities with the effects lead by sodium butyrate. 
Previous investigations also discovered the inhibition of ERK pathway in K562 cells. 
In the K562 differentiation process, the enhancement of ERK pathway leads the cells 
to diffentiate into megakaryocytes, while inhibition of ERK or activation of p38 
MAPK pathway leads cells to erythroid phenotype. Hence, the activation of p38 
MAPK pathway and the y-globin gene expression leads by hydroxyurea may caused 
by the differentiation of K562 cells in erythroid direction. 
3.5.2. STAT3 phosphorylation at Ser727 site promotes transcription factor 
activity and y-globin gene expression 
Recent evidences have demonstrated the importance of signaling pathways in 
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mediating drug-induced HbF production and the involvement of JAK-STAT pathway. 
Sodium butyrate has been demonstrated to induce erythroid maturation in mouse 
erythroleukemia cells associating rapid phosphorylation of JAK2 and STAT5 
(Yamashita et al. 1998). Enhanced phosphorylation level of STAT3 at Ser727 was 
also found accompanied by activation of p38 MAPK pathway in IL-2 or IL-12 
induced mouse lymphocytes (Gollob et al. 1999). Regarding to the similar 
enhancement scheme of p38 MAPK and increased phosphorylation of STAT3 at 
Ser727 site induced by hydroxyurea in our model, we consider that the increased 
transcription activity of y-globin gene was mediated by activated STAT3 under 
hydroxyurea induction. 
However, it should be noticed that neither increased p38 phosphorylation level nor 
increased STAT3 phosphorylation on Ser727 site was found in Cucurbitacin D-treated 
groups. Hence, it implies a different induction mechanism of Cucurbitacin 
D-induced y-globin gene expression, which does not go through the mediation of p38 
MAPK pathway. 
3.5.3. The role of JAK2-STAT3 activation during y-globin gene activation 
Recently the investigation of y-globin gene regulation mechanism mainly focused on 
the promoter region and organization of different transcription factors, and only 
limited research paid attention on the aspect of cell signaling and fetal hemoglobin 
production. The JAK2-STAT3 signaling pathway, which has been implicated in 
sodium butyrate-induced y-globin gene activations,(Xie et al. 1999; Foley et al. 2002) 
is considered helpful for specific gene-based treatments on hematopoiesis deficiencies. 
Another important pathway that considered important for y-globin gene regulation is 
p38 MAPK pathway, along with its direct link between 7-globin gene inducibility and 
histone deacetylace inhibitors (HDAIs). 
In our research, we presented two different but intercrossing signaling pathways that 
responsible for either Cucurbitacin D or hydroxyurea-induced y-globin gene 
activation. Cucurbitacin D, which activates JAK2 and then triggers phosphorylation 
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of downstream transcription factor STAT3 on Tyr705 site, elicits the enhanced 
translocation of STATS into nucleus thus binding to y-promoter region and initiates 
Y-globin gene expression. Similar activation of JAK2-STAT3 cascade has been 
reported in EPO-induced UT7/EP0 cell line. This activation mechanism was 
considered to be STAT1/STAT3 related mitogenesis-associated molecules and 
over-expression of c-myc gene (Fukada et al. 1998; Kiuchi et al. 1999). Another 
rapid activation of JAK2 ant STATS induced by sodium butyrate was also reported 
(Yamashita et al. 1998)，and implies the common pathway shared by y-globin gene 
inducers. 
In contrast, hydroxyurea may play as a multi-role inducer. In one way it possesses a 
similar behavior as Cucurbitacin D by promoting the phosphorylation of STATS on 
Tyr705 site. In another way, it also activates the p38 MAPK cascade and causes 
STATS phosphorylation on Ser727 site, in a similar manner of sodium butyrate and 
trichostatin-induced y-globin gene expression. Regarding there will always be a 
basal level of phosphorylated STATS presence in cytoplasm, either of two alternative 
phosphorylation sites activate the STATS and led to its migration into nucleus. 
Migrated STATS binds to the STATS consensus sequence located on the y-promoter 
and hence activates gene transcription. Since the STATS consensus sequence is also 
included in the promoter region of 8, 5’ and P globin genes,(Foley et al. 2002) the 
drug induction will also promote transcription of genes indicated above, as 
demonstrated by real-time RT-PCR results. 
However, the idea that hydroxyurea may possess a dual-activator mechanism cannot 
be excluded. Researches using sodium butyrate as y-globin gene inducers proposed 
both the histone-hyperactylation accompanied chromatin structural changes and 
transcription factor activation by p38 MAPKs or JAK2-STAT3s are both essential for 
a maximal expression of y-globin gene. 
3.5.4. Inhibitor assay 
Our experiment results also suggested that activated STATS plays a crucial role in 
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Y-globin gene activation. The results not only support a direct connection between 
Y-globin gene inducibility and STAT3 activation, but also imply a total abolishment of 
STAT3 activity negatively regulates y-globin gene expression. In our two 
experiments, one abolished the phosphorylation of Tyr705 site on STAT3 by AG490 
treatment, another abolished the phosphorylation of Ser727 site on STAT3 by p38 
inhibitors treatment, both resulted in greatly reduced fetal hemoglobin production in 
K562 cells under drug induction. Hence, the maintenance of basal phosphorylation 
level on both Tyr705 and Ser727 sites is essential for the y-globin gene activity. 
Results from MAPK kinase inhibitor assay clearly indicated that out of three different 
subgroups of MAPK family, only p38 MAPK was essential for the successful 
induction of fetal hemoglobin in K562 cells. Pre-treatment using either JNK/SAPK 
inhibitors or ERK inhibitors demonstrated no significant results for the reduced fetal 
hemoglobin production. Hence, we propose the following mechanisms were 
involved during abolishment of fetal hemoglobin production by p38 inhibitors. In 
normal cells, the phosphorylation of STAT3 on Ser727 is maintained by the activity of 
p38 MAPK at its basal level. Regarding the p38 MAPK has the property of 
autophosphorylation, it ensures the presence of a small portion of activated p38 
MAPK in cytoplasm. The activated p38 MAPK thus takes the responsibility to keep 
the STAT3 Ser727 phosphorylation at a certain level to ensure proper function of gene 
regulation. However, pre-treatment of inhibitors abolished the kinase function of 
p38 MAPK and failed in keeping the basal level of STAT3 Ser727 phosphorylation 
mediated by p38 MAPK. Previous research indicated that an increase of basal level 
of STAT3 Ser727 phosphorylation may be observed in p38 MAPK inhibitor-treated 
cells that was led by MKK6-induced activation of unidentified Ser/Thr kinase, 
however, it is noteworthy that the enhancement of STATS Ser727 phosphorylation 
level was not able to mediate its normal transcription-enhancing function (Xu et al. 
2003). In other words, the p38 MAPK inhibitor pre-treatment abolished the normal 
STAT3 function. 
In CuD-trated groups, although CuD induction does not directly affect the STAT3 
phosphorylation on Ser727 site, the abolishment of p38 MAPK activity still inhibited 
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normal STATS function thus prevented enhanced fetal hemoglobin production. In 
HU-treated groups, since the enhanced fetal hemoglobin production was a direct 
consequence of p38 activation, inhibition of p38 activity leads to reduced drug effect 
and fetal hemoglobin production. 
Results from JAK-STAT kinase assay also indicate that the phosphorylation of STAT3 
on Tyr705 site is essential for successful induction of fetal hemoglobin in K562 cells. 
Pre-treatment of JAK-STAT pathway inhibitor AG490 reduced drug-induced HbF 
production in both CuD and HU-induced groups. Some members that belong to the 
Cucurbitacin family, Cucuribitacin A, B, E, I and Q, has demonstrated their effects 
towards STAT3 phosphorylation on Tyr705 site (Sun et al. 2005; Graness et al. 2006; 
van Kester et al. 2008). However, the detailed effecting mechanism of Cucurbitacin 
family members differs from one to another. Treatment using Cucurbitacin B, E, and 
I towards A549 cells significantly reduced phosphorylated JAK2 and STAT3 Tyr705 
in western blot results. Cucurbitacin Q only inhibited the phosphorylation of STAT3 
Tyr705 without affecting the JAK2 phosphorylation. In contrast, though 
Cucurbitacin A inhibited the phosphorylation of JAK2, it enhanced phosphorylation 
level of STAT3 on Tyr705 site (Sun et al. 2005). Hence, the effects of different 
Cucurbitacins towards STAT3 phosphorylation cannot be generalized. According to 
the experiment results, it is assumed that maintenance of STAT3 Tyr705 site is 
essential for both CuD and HU-induced fetal hemoglobin production. 
Previous researches on y-globin gene expression have indicated the importance of 
JAK-STAT pathway and p38 MAPK pathway, but failed in establishing reasonable 
connections and regulation scheme upon these two different regulation system. 
According to our experiment results, it can be concluded that functional STAT3 
activity is essential for the y-globin gene expression in K562 cell line. Although the 
two STAT3 phosphorylation sites were regulated by different pathways, inhibition on 
either of the upstream regulators will results in reduced overall activity of STAT3. 
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3.5.5. Relations between STAT3 nuclear translocation and enhanced fetal 
hemoglobin production 
In this section, the role of STAT3 during drug-induced y-globin gene activation is 
further confirmed using gel retardation assay and confocal imaging. Previous 
researches have identified one STAT3 motif (TTCTGGAA) located in the 
5'-untranslated region of y-globin gene with structural similarities to the IL-6 
responsive element in a2-macroglobulin gene (Zhang et al. 2001). EMS A results 
indicated the binding of a heterodimeric STAT1-STAT3 complex to the motif region 
might contributed to the steady-state expression of y-globin gene. This STAT3 
homolog sequence was observed in the analogous position of e, 6, and P-globin genes, 
which suggested further evidence for physiologic role for STAT family proteins 
during globin gene regulation (Foley et al. 2002). Our EMSA experiments using 
short DNA probes including STAT3 motif revealed enhanced protein binding 
activities to the motif region under CuD/HU induction, which suggested the activated 
STAT3 indeed translocated into nucleus and bind on target sequence to trigger gene 
transcription. 
However, this result is contradictory to previous researches, which suggested an 
inhibitory role of activated STATS towards y-globin gene expression (Foley et al. 
2002). This may be explained by the different activation methods and STAT3 
isoforms. The activation of STAT3 by either overexpression of STAT3p or IL-6 
induction repressed y-promoter activity was considered by enhanced binding affinity 
to AySTATS region and complex formation. In our model, both isoforms of STAT3 
were activated, which suggested different components might be involved during 
transcription complex forming thus leading to the enhanced transcription activity. 
Besides, inhibition of STAT3 on either of the phosphorylation site resulted in 
repression of y-globin gene expression and fetal hemoglobin production, suggested 
the positive role of STAT3 towards y-promoter activity. 
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4. Summery and Prospect 
Recently the investigation of y-globin gene regulation mechanism mainly focused on 
the promoter region and organization of different transcription factors, and only 
limited research paid attention on the aspect of cell signaling and fetal hemoglobin 
production. The JAK2-STAT3 signaling pathway, which has been implicated in 
sodium butyrate-induced y-globin gene activations, (Xie et al. 1999; Foley et al. 2002) 
is considered helpful for specific gene-based treatments on hematopoiesis deficiencies. 
The activation of JAK2 and STATS during erythroid maturation induced by sodium 
butyrate has been demonstrated in mouse erythroleukemia cells (Yamashita et al. 
1998). Researches using UT7/EP0 cells observed induction of EPO was 
accompanied by activation of JAK2 and phosphorylation of STAT3 at Tyr705 site, 
and implied a positive effect of STAT3 phosphorylation for erythroid-directed cell 
differentiation (Kirito et al. 2002). Another important pathway that considered 
important for y-globin gene regulation is p38 MAPK pathway, along with its direct 
link between y-globin gene inducibility and histone deacetylace inhibitors (HDAIs) 
(Pace et al. 2003). Up to now, several trans-activators of butyrate responsive 
elements have been identified (Bohan et al. 1989; Ikuta et al. 1998; Pace et al. 2000). 
Enhanced phosphorylation level of STAT3 at Ser727 was also found accompanied by 
activation of p38 MAPK pathway in IL-2 or IL-12 induced mouse lymphocytes 
(Gollobetal. 1999). 
In our research, we presented two different but intercrossing signaling pathways that 
responsible for either Cucurbitacin D or hydroxyurea-induced y-globin gene 
activation. Cucurbitacin D, which activates JAK2 and then triggers phosphorylation 
of downstream transcription factor STAT3 on Tyr705 site, elicits the enhanced binding 
affinity of y-promoter region and initiates y-globin gene expression. Some members 
that belong to the Cucurbitacin family, Cucuribitacin A, B, E, I and Q, has 
demonstrated their effects towards STATS phosphorylation on Tyr705 site (Sun et al. 
2005; Graness et al. 2006; van Kester et al. 2008). However, the detailed effecting 
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mechanism of Cucurbitacin family members differs from one to another. Treatment 
using Cucurbitacin B, E, and I towards A549 cells significantly reduced 
phosphorylated JAK2 and STAT3 Tyr705 in western blot results. Cucurbitacin Q 
only inhibited the phosphorylation of STAT3 Tyr705 without affecting the JAK2 
phosphorylation. In contrast, though Cucurbitacin A inhibited the phosphorylation 
of JAK2, it enhanced phosphorylation level ofSTAT3 on Tyr705 site (Sun et al. 2005). 
Hence, the effects of different Cucurbitacins towards STAT3 phosphorylation cannot 
be generalized. Hydroxyurea may play as a multi-role inducer. In one way it 
possesses a similar behavior as Cucurbitacin D by promoting the phosphorylation of 
STAT3 on Tyr705 site. In another way, it also activates the p38 MAPK cascade and 
leads STAT3 phosphorylation on Ser727 site, in a similar manner of sodium butyrate 
and trichostatin-induced y-globin gene expression. Regarding there will always be a 
basal level of phosphorylated STAT3 presence in cytoplasm, enhancement on either of 
two alternative phosphorylation sites activate the STAT3 and lead to its migration into 
nucleus. Migrated STAT3 binds to the STAT3 consensus sequence located on the 
7-promoter and hence activates gene transcription. Since the STAT3 consensus 
sequence is also included in the promoter region of e, 5，and p globin genes,(Foley et 
al. 2002) the drug induction will also promote transcription of genes indicated above, 
as our previous research data suggested (data not shown). 
Our experiment results also suggested that activated STAT3 plays a crucial role in 
Y-globin gene activation. The results not only support a direct connection between 
Y-globin gene inducibility and STATS activation, but also imply a total abolishment of 
STATS activity negatively regulates y-globin gene expression. In our two 
experiments, one abolished the phosphorylation of Tyr705 site on STAT3 by AG490 
treatment, another abolished the phosphorylation of Ser727 site on STATS by p38 
inhibitors treatment, both resulted in greatly reduced fetal hemoglobin production in 
K562 cells under drug induction. Hence, we propose the following mechanisms 
were involved during abolishment of fetal hemoglobin production by p38 inhibitors. 
In normal cells, the phosphorylation of STAT3 on Ser727 is maintained by the activity 
of p38 MAPK at its basal level. Regarding the p38 MAPK has the property of 
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autophosphorylation, it ensures the presence of a small portion of activated p38 
MAPK in cytoplasm. The activated p38 MAPK thus takes the responsibility to keep 
the STATS Ser727 phosphorylation at a certain level to ensure proper function of gene 
regulation. However, pre-treatment of inhibitors abolished the kinase function of 
p38 MAPK and failed in keeping the basal level of STAT3 Ser727 phosphorylation 
mediated by p38 MAPK. Previous research indicated that an increase of basal level 
of STATS Ser727 phosphorylation may be observed in p38 MAPK inhibitor-treated 
cells that was led by MKK6-induced activation of unidentified Ser/Thr kinase. 
However, it is noteworthy that the enhancement of STAT3 Ser727 phosphorylation 
level was not able to mediate its normal transcription-enhancing function (Xu et al. 
2003). Hence, the maintenance of basal phosphorylation level on both Tyr705 and 
Ser727 sites is essential for the "y-globin gene transcriptional activity. 
In general, our data support two alternative pathways for "y-globin gene activation as 
shown in Figure 11. The activation of JAK2 mediated by Cucurbitacin D is assumed 
to be elicited by membrane-bound receptors, probably members of GP130 
family.(Taga et al. 1997; Xie et al. 1999) Activated JAK2 phosphorylates 
cytoplasmic STAT3 at Tyr705 site and triggers translocation of STAT3 into nucleus. 
Migrated STAT3 therefore binds to STAT3 consensus sequence located on the 
promoter region of y, e, 5，and p globin genes and initialize enhanced transcription 
activity, finally led to increased synthesis of globin products. The mechanism of p38 
MAPK pathway initialization mediated by hydroxyurea remains unknown, probably 
through similar manners as sodium butyrate and trichostatin.(Park et al. 2001) 
Activated p38 MAPK cascade finally phosphorylates STAT3 at Ser727 site and leads 
to similar nuclear migration pattern and globin gene activation. Regarding that 
dual-phosphorylation of STATS is required for its translocation and binding to 
consensus sequences, the maintenance of JAK2 and p38 MAPK at basal level is 
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Figure 11. Proposed experimental model for the role of JAK2-STAT3 and p38 MAPK pathways 
in CuD and HU-induced y-globin gene activation. Schematic chart is presented for the signal 
transduction events occurred in CuD and HU-induced y-globin gene activation, and two 
alternative ways are shown to be responsible for the initialization of gene transcription. 
Hydroxyurea, which is represented by blue triangle, initializes the p38 MAPK cascade 
activation by activating JAK2 kinase. Activated p38 MAPK migrates into nucleus and 
phosphorylates transcription factors binding to either promoter region (STATs) or accessory TF 
motif thus promotes transcription activity. Cucurbitacin D, which is represented by green 
triangle, might interact with unknown membrane-bound receptors of GP130 family thus 
activate JAK2. Activated JAK2 phosphorylates STATS at Tyr705 site, causing its dimerization 
and translocation into nucleus. Phosphorylated STATS finally binds to promoter region of 
Y-globin gene and promotes transcription activity. Blue solid lines resemble the main y-globin 
gene activation pathway mediated by Cucurbitacin D induction; red clotted lines resemble 
pathway mediated by hydroxyurea. 
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Further exploration of Cucurbitacin D from Trichosanthes kirilowii offered promising 
ideas on p-thalassemia treatment through gene switch protocol. Previous and 
ongoing research from our laboratory both indicated the Cucurbitacin D demonstrated 
to be more effective and reliable comparing the current y-globin inducer hydroxyurea. 
The detailed mechanism of signal transduction during drug-induced y-globin gene 
activation is essential for the functional analysis of y-promoter function. Previous 
researches done by our lab revealed the relations between MAPK pathways and 
Y-globin gene activation. Here, we provided a more complete scheme of signal 
transduction pathways towards y-globin gene activation, with two different starting 
signal molecules and one central transcription factor STAT3. With the discovery of 
STAT3 consensus sequence located in different globin promoter region, our research 
offered key insights into the regulation system of globin gene expression mechanism. 
Further investigation is required to reveal the detailed regulatory mechanism of 
transcription factors and their interaction with y-promoters. Besides STAT3, 
members of GATA and NF-E family have been reported to play important roles in 
competition with STAT3 on y-promoter region thus regulated transcription activity. 
Transient over-expression of GATA-1 in K562 cell line demonstrated stabilized 
transcription activity of y-globin mRNA (Morceau et al. 2000). Mutations on 
GATA-1 binding site located on y-promoter also showed hereditary persistence in 
altered fetal hemoglobin expression scheme in transgenic mice model (Liu et al. 
2005). Hence, it would be profitable to explore whether CuD and hydroxyurea 
interacted with indicated transcription factors thus exerted their effects on 7-globin 
gene expression. 
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